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Abstract
Cancer cells in hypoxic areas of solid tumors are to a large extent protected against the action of
radiation as well as many chemotherapeutic drugs. There are, however, two different aspects of the
problem caused by tumor hypoxia when cancer therapy is concerned: One is due to the chemical
reactions that molecular oxygen enters intoin therapeutically targeted cells. This results in a direct
chemical protection against therapy by the hypoxic microenvironment which has little to do with
cellular biological regulatory processes. This part of the protective effect of hypoxia has been known for
more than half a century and has been studied extensively. However, in recent years more focus has
been put into the other aspect of hypoxia, namely the effect of this microenvironmental condition on
selecting cells with certain genetical pre-requisites that are negative with respect to patient prognosis.
There are adaptive mechanisms, where hypoxia induces regulatory cascades in cells resulting in a
changed metabolism or changes in extra cellular signalling. These processes may lead to changes in
cellular intrinsic sensitivity to treatment irrespective of oxygenation and furthermore, may also have
consequences for tissue organization. Thus, the adaptive mechanisms induced by hypoxia itself may
have a selective effect on cells with a fine-tuned protection against damage and stress of many kinds. It
therefore could be that the adaptive mechanisms may be taken advantage of for new tumor
labelling/imaging and treatment strategies.  One of the Achilles' heels of hypoxia research has always
been exact measurements of tissue oxygenation as well as control of oxygenation in biological tumor
models. Thus, development of technology that can ease this control is vital in order to study mechanisms
and perform drug development under relevant conditions. An integrated EU Framework project
2004-2009, termed Euroxy, demonstrates several pathways involved in transcription and translation
control of the hypoxic cell phenotype and evidence of cross talk with responses to pH and redox
changes. The carbon anhydrase isoenzyme CA IX was selected for further studies due to its expression
on the surface of many types of hypoxic tumors.  The effort has lead to marketable culture flaks with
sensors and incubation equipment and the synthesis of new drug candidates against new molecular
targets. New labelling/imaging methods for cancer diagnosing and imaging of hypoxic cancer tissue
now are being tested in xeno-graft models and also are in early clinical testing while new potential
anticancer drugs are undergoing tests using xenografted tumor cancers. The present paper describes the
above results in individual consortium partner presentations.
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abstract
Cancer cells in hypoxic areas of solid tumors are to a large extent protected against the action of radiation as well as 
many chemotherapeutic drugs. There are, however, two different aspects of the problem caused by tumor hypoxia 
when cancer therapy is concerned: One is due to the chemical reactions that molecular oxygen enters into therapeu-
tically targeted cells. This results in a direct chemical protection against therapy by the hypoxic microenvironment, 
which has little to do with cellular biological regulatory processes. This part of the protective effect of hypoxia has 
been known for more than half a century and has been studied extensively. However, in recent years there has been 
more focus on the other aspect of hypoxia, namely the effect of this microenvironmental condition on selecting cells 
with certain genetic prerequisites that are negative with respect to patient prognosis. There are adaptive mechanisms, 
where hypoxia induces regulatory cascades in cells resulting in a changed metabolism or changes in extracellular 
signaling. These processes may lead to changes in cellular intrinsic sensitivity to treatment irrespective of oxygenation 
and, furthermore, may also have consequences for tissue organization. Thus, the adaptive mechanisms induced by 
hypoxia itself may have a selective effect on cells, with a fine-tuned protection against damage and stress of many 
kinds. It therefore could be that the adaptive mechanisms may take advantage of for new tumor labeling/imaging and 
treatment strategies. One of the Achilles’ heels of hypoxia research has always been the exact measurements of tissue 
oxygenation as well as the control of oxygenation in biological tumor models. Thus, development of technology that 
can ease this control is vital in order to study mechanisms and perform drug development under relevant conditions. 
An integrated EU Framework project 2004–2009, termed EUROXY, demonstrates several pathways involved in tran-
scription and translation control of the hypoxic cell phenotype and evidence of cross-talk with responses to pH and 
redox changes. The carbonic anhydrase isoenzyme CA IX was selected for further studies due to its expression on the 
surface of many types of hypoxic tumors. The effort has led to marketable culture flasks with sensors and incubation 
equipment, and the synthesis of new drug candidates against new molecular targets. New labeling/imaging methods 
for cancer diagnosing and imaging of hypoxic cancer tissue are now being tested in xenograft models and are also in 
early clinical testing, while new potential anti-cancer drugs are undergoing tests using xenografted tumor cancers. The 
present article describes the above results in individual consortium partner presentations.
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1. Introduction
Due to lower or more erratic overall blood flow in malignant 
compared to normal tissues, solid tumors generally contain 
smaller or larger areas where cells have far less than normal 
access to oxygen1. This was first indicated as early as the 
1930s2, and was related to a possible relevance to radiother-
apy, since earlier observations3 had indicated that oxygen 
increased radiosensitivity in developing eggs of the parasitic 
nematode Ascaris.
Within this field, the term “hypoxia” became a standard 
notion when referring to cells having a microenvironment 
with less oxygen than that of normal tissues (40–50 M). The 
definition is, however, vague, since even the level of oxygen-
ation in normal tissues may vary, and this variation by itself 
is of importance for normal tissue regulation.
Traditionally, the finding of hypoxic areas in solid human 
cancer tumors, as reported by Thomlinson and Gray4, was 
viewed as being primarily a problem for radiation therapy5. 
The hypothesis was that not all hypoxic cancer cells die due 
to low oxygen, since some are necessarily located near the 
rim of the hypoxic areas and it takes some time for cells to 
die even during extremely low oxygenation. The radioresist-
ance of hypoxic cells was later found to be related to the high 
electron affinity of the molecule6, which enables even small 
amounts of oxygen to fixate radiation-induced macromolecu-
lar damage before the damage can be repaired by naturally 
occurring radical scavengers in the cells. Since tissue hypoxia 
is restricted primarily to malignant and not normal tissues, it 
was postulated that hypoxia represents a specific protection 
against radiation for malignant compared to normal cells.
Later it was seen that this specific protection was not 
limited to radiation, but even included some chemothera-
peutic drugs7,8. This has partly been attributed to the fact that 
hypoxic cells are located far from the nearest blood vessel, 
and therefore may experience limited influx of the drug, but 
it has also turned out to be due to a specifically reduced sen-
sitivity to some drugs under hypoxic conditions9.
In order to increase the radiosensitivity of hypoxic cells 
without affecting that of well-oxygenated (i.e. normal) cells, 
drugs denoted hypoxic cell sensitizers were developed. 
These should preferentially have some of the same electron-
affinity as oxygen itself10. There were, however, two important 
differences compared to oxygen: (1) these drugs should not 
be metabolized by the cells: in that way they would be able 
to diffuse into the hypoxic areas; (2) the drugs should have 
some of the same electron-affinity as oxygen and therefore 
also the ability to fixate radiation-induced damage. They 
should be somewhat less effective than oxygen, though: in 
that way they would not increase the radiosensitivity of well-
oxygenated (i.e. normal) cells.
Although the sensitizer compounds developed should in 
principle be non-toxic to cells, some of them turned out to be 
interesting from a chemotherapeutic (and diagnostic) point 
of view. The hypoxic cell sensitizers acted as targets for one-
electron reductases such as cytochrome P45011. The addition 
of an electron started a progression toward the development 
of a toxic compound. Thus, the hypoxic cell sensitizer acted 
as a non-toxic prodrug12. The positive thing was that the tox-
icity only developed under hypoxic conditions since oxygen, 
if present, captured the electron and reversed the process 
back to the non-toxic prodrug. Thus, for the first time there 
were drugs developed that had a potential specificity against 
severely hypoxic and not aerobic cells. Another possibility 
that was opened by these hypoxia-specific compounds was 
that they could be used as markers to detect and even visual-
ize hypoxic regions in tumor tissue.
A large part of the survival and treatment resistance of 
deoxygenated cells is conferred by signaling pathways that 
are specifically active under hypoxic pO
2
. During the last 
15 years the cellular oxygen sensing mechanism of meta-
zoan cells and the cascade of regulatory mechanisms that 
is triggered by the sensing of reduced oxygenation has 
been intensively studied, particularly in regard to the pre-
dominant hypoxia-sensing machinery: that of the hypoxia-
inducible transcription factor HIF13. Regulatory processes 
in the HIF casacde involve, as a first step, deactivation of 
prolyl hydroxylase domain (PHD) proteins by the reduc-
tion in oxygen concentration, and are triggered at oxygen 
levels within the range experienced even by normal cells14. 
Although the oxygen levels where PHD deactivation takes 
place are close to that of normal tissue, they are neverthe-
less denoted hypoxia, and the term is often used and under-
stood as synonymous to the term hypoxia used to describe 
the cancer-specific low oxygenation causing resistance to 
therapy. It could, however, be that tumor hypoxia and the 
PHD-sensing hypoxia are so different that the two concepts 
should not be mixed. The reason why this is uncertain is that 
the scientific work within the field of hypoxia is still largely 
done without exact knowledge of the pericellular oxygena-
tion. Measurement as well as maintenance of oxygenation 
in cellular microenvironments is so challenging and techni-
cally time-consuming that exact pericellular measurements 
are usually not performed. The problem of experimental 
reproducibility is instead taken care of by other means, 
for example culturing of cells in glove-boxes with a known 
and well-controlled atmospheric oxygen concentration. If 
cell culturing techniques are standardized with respect to 
timing and density of cells, one may then obtain reproduc-
ible conditions within one laboratory without any direct 
measurement of oxygen at the cell membrane. It is far from 
obvious, however, that microenvironmental oxygenation 
between different laboratories can be compared.
Several mechanisms in the regulatory cascades starting 
by deactivation of PHD and stabilization of HIF may have 
potential as mechanisms for new cancer drug development. 
There is still some uncertainty with respect to the cancer-
specificity of these regulations.
Later still it was, however, experienced that low oxygen 
generally has profound consequences with regard to cell 
behavior, both in the form of the role that molecular oxygen 
plays in the regulation/deregulation of key cellular enzymes 
(i.e. dihydro-orotate dehydrogenase or ribonucleotide 
reductase, which are vital for supply of precursors for DNA 
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synthesis) and in terms of the role it plays in regulation of 
gene transcription (HIF) and translation.
Mostly due to the fact that normal tissue in most cancer 
patients is not hypoxic, hypoxia offers a broad range of can-
cer-related mechanisms with the potential for improvement 
of therapy and diagnosis. The theme of the EUROXY project 
is: “Taking advantage of tumor cell adaptations to hypoxia 
for developing new tumor markers and treatment strate-
gies”. More than 20 research groups covering different areas 
of research within this vast field have collaborated over the 
last 5 years and have supported each other with ideas and 
possibilities. The research has covered:
development of new technology for continuous moni-•	
toring of pericellular oxygen concentration and respira-
tion rate during in vitro cell culturing
studies of the role of the cancer-specific carbonic •	
anhydrase (CA) IX in pH regulation with the aim to 
develop CA IX as a possible target for therapy as well 
as diagnosis
studies of design and synthesis of new drugs for CA IX •	
inhibition as well as bioreductive drugs
fundamental studies of cell cycle control under •	
hypoxia
studies of new types of radiation delivery to selectively •	
increase the radiosensitivity of hypoxic cells
fundamental studies giving new knowledge concerning •	
PHD oxygen sensing on concomitant regulatory cas-
cades through HIF
fundamental studies concerning protein synthesis •	
(translation) and splicing.
In the following these different themes are described 
under separate headings.
2. The EUROXY Program
A characteristic of EUROXY is the many years of build-
ing up the necessary scientific and collaborative strength 
to take on an integrated European Union (EU) project. 
Many of the EUROXY members were previously members 
of two hypoxia-focused projects supported by regional 
(Scandinavian) sources, then members of an EU-funded 
infrastructure project (Oxnorm), and now the integrated 
project EUROXY.
This continuity in scientific focus and scientific partners 
made each effort a stepping stone for the next joint project. 
Actually, already after the first 2 years of work on EUROXY, a 
decision to seek extension of the collaboration beyond the 
5 years was taken. The proposal was to take the preclinical 
EUROXY results and seek funding for their translation into 
clinical testing. After the inclusion of strong clinical groups, 
EU funding of the successor program was ensured.
The EUROXY predecessor Oxnorm included a develop-
ment of concepts and nomenclature. One attempt to explic-
itly define what hypoxia should stand for in cellular biology 
was not to relate it to measured pericellular oxygen tension 
in absolute terms but to consider hypoxia as a variable, i.e. 
the pericellular tension which, for particular tissues/cells, 
makes the cells switch on their adaptive metabolic mecha-
nisms induced by the lowered oxygen tension. However, 
no consensus was reached on the definition, but there was 
agreement on the need for pericellular oxygen tension 
measurements in order to facilitate reproducibility and 
comparison of results.
The follow-up study EUROXY was largely shaped by the 
recent finding of a central role of the transcription regulator 
HIF and its effect on many downstream gene functions15, and 
the emerging evidence of a role of HIF in such varied areas 
as microbiology, immunology, cardiology, etc. Our general 
working hypothesis became that the cellular responses 
to hypoxia allowing tumor cells to survive the low oxygen 
tension in solid tumors, which at the same time shielded 
the tumor cells against ionizing irradiation, and many cyto-
statics might themselves represent novel targets for tumor 
imaging/labeling and anti-tumor therapy.
The means to take advantage of this concept was a 
concerted basic cellular and molecular study of hypoxic 
response pathways, and, when promising targets were iden-
tified, find the labeling/therapeutic agents in preparation for 
future clinical testing.
Our focus on HIF-related pathways was soon found to be 
insufficient, because the growing number of downstream 
functions governed by HIF indicated that a high number 
of side effects would result if one made HIF itself the thera-
peutic target. Our focus was widened, and more effort went 
into unraveling the upstream oxygen-sensing hydroxylases 
and later also into translation research on the unfolded pro-
tein response (UPR) and mammalian target of rapamycin 
(mTOR).
An important consideration in the last year of EUROXY 
has been to ensure optimal utilization of obtained results. 
A part of this effort is the present article. Another part is 
the participating companies’ representation in the mar-
ket of antibodies, sensors, incubators, and compounds for 
imaging. Third, we have secured a continuation program, 
Metoxia, funded by the EU.
3. Technical aspects of measuring oxygen 
tensions in vivo and in vitro
3.1. Introduction
Oxygen sensors for in vivo and in vitro application mainly 
use two principles: optical sensor probes, consisting of 
fluorescence dyes, and electrochemical sensor electrodes. 
Both in vivo and in vitro, there is an undisputed need for 
more practicable and cost-effective means of monitoring 
pericellular oxygen tension, as compared to the currently 
commercially available brittle and expensive oxygen 
probes. This vision has guided us toward the development 
of sensor chips permanently mounted in a cell culture 
flask, as well as a polymeric oxygen sensor array strip with 
a stability of sensitivity of 2 weeks, in a cost-effective fabri-
cation flow.
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3.2. Oxygen microsensors
Optical sensors use a dye to measure oxygen tension by eval-
uating the quenching effect due to the presence of oxygen 
molecules16. As dyes usually tend to bleach during opera-
tion, a modulated excitation light is used, enabling perform-
ing lifetime analysis to obtain sensor readings independent 
of the bleaching17. This principle allows stable readings over 
time, but has no defined zero-point, which hampers the 
calibration and application of such sensors for low oxygen 
situations as often found in hypoxic cell cultures. The main 
advantage of the optical approach is that the measurement 
does not consume any oxygen.
Electrochemical oxygen sensors are usually ampero-
metric sensors, where the oxygen is reduced at an appro-
priate metal electrode. There are also some potentiometric 
 dissolved oxygen sensors18, which have—like the optical 
 sensors—no defined zero-point. Amperometric oxygen sen-
sors can be distinguished as Clark-type and direct ampero-
metric sensors. The main improvement that Clark made 
regarding oxygen sensors was to cover the electrode arrange-
ment with a gas-permeable membrane19. This was later often 
referred to as the Clark-type sensor, where the measurement 
region was separated from the electrolyte chamber by a gas-
permeable membrane. An example of realization of such a 
sensor type in microtechnology was made by Jobst et al.20. 
This sensor type has the advantage that degradation of the 
sensor’s response due to substances from the measurement 
medium is avoided, overcoming either the need for frequent 
recalibration or the implementation of advanced opera-
tional procedures.
On the other hand, the fabrication of Clark-type sensors 
in microtechnology is cumbersome, and so far such devices 
have failed to provide the desired operational lifetime. 
Therefore, nowadays cell culture sensors deal with direct 
amperometric setups21–23.
To overcome the effect of performance-degrading sub-
stances from the cell culture medium, chronoamperometric 
protocols are used to ensure signal stability over a range of 
weeks. These protocols for application with platinum elec-
trodes comprise cleaning steps, with which a platinum oxide 
layer is formed on the electrode and removed immediately 
before the reduction of oxygen, forcing the rapid establish-
ment of long-term stable surface conditions for oxygen 
reduction. Furthermore, by setting an appropriately short 
on-time, the inherent disadvantage of amperometric oxygen 
sensors—consumption of the analyte—can be minimized.
To obtain pericellular oxygen readings in vitro, two 
approaches have been realized. One is with a chip sensor, 
where the cells settle directly on the chip surface. The second 
approach is to use a sensor array strip, which can be inserted 
through the neck or an additional opening into the cell cul-
ture flask. These strips measure the oxygen concentration 
at different height levels simultaneously, which allows—
assuming stable diffusion profiles—extrapolation of peri-
cellular oxygen levels and the cells’ oxygen consumption at 
the same time. Alternatively, conventional single-electrode 
dip-in sensors can be used to measure the oxygen partial 
pressure at different height levels by means of an automated 
motorized stage24.
For both approaches, the sensor materials must not show 
any cytotoxic effects with the used cell cultures. A sensor 
chip, where adherent cells have to settle directly on the chip 
surface, must comprise a top layer that is not only non-
cytotoxic, but further allows cells to adhere well. The cells 
should behave during proliferation similar to the situation 
in an ordinary cell culture flask. We found that a plasma-
deposited silicon oxide fulfills these requirements for the 
tested human breast cancer cell lines (MCF-7 and T-47D).
3.3. Sensing cell culture flask
During the EUROXY project, the concept and prototypes for 
a sensing cell culture flask (SCCF) were developed (Figure 1). 
The SCCF is based on a conventional 50 mL cell culture flask, 
where a sensor chip is integrated in a milled opening in the 
bottom of the flask in such a way that the chip surface is on a 
plane with the surface of the cell culture area in the flask.
The SCCF chip comprises four platinum oxygen electrodes 
along with a common counter and a silver/silver chloride 
reference electrode. Further, the SCCF chip can be equipped 
with metal oxide electrodes for pH-respective acidification 
measurements and working electrodes for a NO sensor.
The SCCF chip is fabricated with thin-film platinum 
electrodes on a Pyrex wafer. The platinum is insulated with 
an inorganic plasma-deposited (plasma enhanced chemi-
cal vapor deposition, PECVD) multilayer. These layers are 
opened at the electrode positions by reactive ion etching 
(RIE). The layer setup is, despite the region of the electrodes 
and connection lines, optically transparent, and therefore 
allows inspection of the cell culture by inverted microscopy. 
The electrodes are covered with a dispensed poly(2-hydrox-
yethylmethacrylate) (pHEMA)-based hydrogel to ensure 
that cells which adhere on the chip do not settle directly 
on the electrode surface. At the four working electrodes for 
oxygen, this hydrogel also acts as a region with lower oxygen 
diffusion coefficient, to confine the major drop of the oxy-
gen gradient toward the electrodes inside the hydrogel. This 
minimizes disturbance of the pericellular oxygen profile. The 
Figure 1. Sensing cell culture flask (SCCF). A sensor chip, comprising 
oxygen and optional pH and NO sensors, is integrated in a standard cell 
culture flask.
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6  Peter Ebbesen et al.
integrated reference electrode is made by electrodeposition 
of silver and subsequent partial electrochemical conversion 
of silver in a chloride solution to silver chloride.
3.4. Oxygen sensor array strips
The all-polymeric devices are made by patterned metal-
lization of a polyimide foil, subsequent insulation, galvanic 
processing, and final laser cutting. Inspired by biocompatibil-
ity considerations, originally an insulation scheme via lami-
nation of a laser-cut thermoset adhesive-coated polyimide 
foil as insulation was used. Though these devices performed 
very well on the timescale of single days, upon prolonged 
continuous use over several days sensitivity of the devices 
increased to an unacceptable extent. This effect originates 
from degradation of the insulation properties. While other 
all-polymeric devices for long-term use—such as connectors 
for cochlear or retina implants—are insulated by means of 
elaborate and expensive processes, applying these technolo-
gies for our application would sacrifice any vision of a cost-
effective device. Our technological innovation now provides 
us with probes having insulation properties preserved for at 
least 2 weeks. Even when fabricated in moderate quantities, 
costs below 10 euros per device seem feasible.
As one can easily imagine from Figure 2, the pericellular 
oxygen concentration is calculated from the linear fit to the 
readings of the four oxygen sensors extrapolated to the flask 
bottom. From this fit, additionally quantification of the oxy-
gen flux or the oxygen consumption by the cells is obtained 
from its slope.
The intrinsic precision of the photo-lithographic method 
for patterning of the insulation layer and improved hydro-
gel membrane composition and deposition even make it 
possible to fabricate devices offering the prospect of over-
coming the need for initial calibration—which would dras-
tically improve the acceptance of such devices by potential 
customers.
While the strip format of the described oxygen sensor 
array is dedicated to in vitro work, translation of the fabri-
cation technology into a needle format is easy, and already 
demonstrated with a 400 µm wide and  50 mm long biosen-
sor probe for in vivo use.
Handling of the probe is another major factor influenc-
ing customer acceptance, as well as measurement reliabil-
ity. Since we consider this a very critical factor, a variety of 
access schemes was realized and presented to the end users. 
The most widely accepted is a permanent mounting of the 
probe through the sidewall of a cell culture flask that allows 
handling of the flask almost like one without an oxygen 
 sensor array.
3.5. Conclusion and outlook
The vision of a robust, easily handled, and cost-effective 
probe for monitoring of the pericellular oxygen concen-
tration in a hypoxic environment was realized by two 
approaches. Currently, cost-effectiveness and ease of han-
dling of the system are still compromised by the assembly 
and interfacing—which will be the focus of future work. This 
work, ideally done with the cooperation of a cell culture flask 
manufacturer, will also provide the platform for the integra-
tion of additional features aiming at oxygen tension and 
metabolite control at individual flask level.
4. Responses to hypoxia in normal and 
malignant cells
4.1. Cellular oxygen sensors
One of the most sensitive (and most studied) physiologi-
cal responses to hypoxia is the massive up-regulation of 
the hematopoietic growth factor erythropoietin (Epo) by 
acute reductions in blood oxygen availability. In the early 
1990s, work on transcriptional control of Epo unexpectedly 
revealed that the underlying system of oxygen sensing and 
transcriptional control operates widely in cells, and is con-
served in essentially all animal species, even those without 
red cell or vascular systems.
Whereas Epo production may increase several hundred-
fold over a matter of hours in response to acute anemia, many 
effects of hypoxia on metabolism and growth/differentiation 
occur over longer timescales, with lower amplitude, and 
(within the intact organism) at apparently different tissue 
oxygen tensions (see above). Despite these contrasts, gen-
etic evidence indicates that a surprisingly large number of 
these responses are dependent on the integrity of the same 
system of oxygen sensing and signaling, involving the post-
translational hydroxylation of the transcription factor HIF. 
This system is activated in cancer by a range of genetic and 
microenvironmental mechanisms, and hence has been one 
of the main focuses of enquiry by the EUROXY consortium.
The pathways regulated by the HIF transcriptional cas-
cade have been reviewed in detail elsewhere25–28. In outline, 
HIF is a heterodimer of  and  subunits. Oxygen sensi-
tive signaling is mediated by the  subunits, of which there 
are three—HIF-1, HIF-2, and HIF-3—each encoded 
at a distinct genetic locus. Oxygen-dependent post-trans-
lational hydroxylation of two conserved prolyl residues 
in the  central degradation domain of HIF-1 and HIF-2 
(and of one prolyl residue in HIF-3) targets the HIF 
polypeptide to the von Hippel–Lindau (pVHL) ubiquitin E3 
ligase and hence destruction by the ubiquitin–proteasome 
pathway (for review see reference 13). In a second oxygen-
regulated step, hydroxylation of an asparaginyl residue 
Figure 2. Micrograph of the sensing tip of a flexible oxygen sensor array 
indicating the mean distance of the individual 200 µm diameter oxygen 
sensors from the cells.
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that is conserved in the C-terminal activation domains of 
HIF-1 and HIF-2 reduces transcriptional activity at least 
in part by blocking the physical association of co-activators 
with this domain. These hydroxylations are all catalyzed 
by non-heme Fe(II) enzymes belonging to the 2-oxoglu-
tarate (2-OG) dependent dioxygenase superfamily. These 
enzymes couple oxidation of the HIF polypeptide to the 
oxidative decarboxylation of 2-OG in an “oxygen split-
ting” reaction that directly consumes molecular oxygen 
(for review see references 29 and 30). Three closely similar 
enzymes termed PHD (prolyl hydroxylase domain) 1, 2, 
and 3 catalyse HIF prolyl hydroxylation. A fourth enzyme 
more closely related to the procollagen prolyl hydroxylases 
(PHD4) has been shown to have in vitro hydroxylase activ-
ity for HIF substrates, though whether it directly targets 
HIF in vivo is uncertain31. To date, a single enzyme FIH 
(factor inhibiting HIF) has been identified that catalyzes 
HIF asparaginyl hydroxylation.
In most members of the Fe(II) and 2-OG dependent oxy-
genase superfamily, including the HIF hydroxylases, three of 
the six available coordination positions at the catalytic iron 
center are utilized for (relatively labile) binding to the apo-
enzyme. This occurs via a 2-histidine-1-carboxylate “facial 
triad” presented by residues on the second and seventh 
strands of the eight-stranded -barrel jelly-role conforma-
tion of the catalytic domain (for review see reference 32). 
This iron coordination arrangement contrasts, for instance, 
with heme enzymes where four of the coordination posi-
tions are generally occupied by the heme. Such differences 
may be relevant to the selection of members of this family of 
enzymes as physiological oxygen sensors. In catalysis, two of 
the remaining three coordination positions are used to bind 
2-OG whilst the sixth is used to bind molecular oxygen. The 
reaction proceeds via a radical mechanism in which the cata-
lytic center is activated (most likely involving the creation of 
a high reactive ferryl species (FeIV=O)), which then oxidizes 
the HIF polypeptide substrate. Ascorbate is required for full 
catalytic activity, and is believed to operate as an alternative 
substrate reducing the catalytic iron center in the event of an 
uncoupled cycle, in which oxidation of HIF fails to occur. It 
appears likely that these diverse co-factor and co-substrate 
requirements are important for the physiological function 
of these enzymes as cellular oxygen sensors, allowing a 
more flexible interface between the availability of molecular 
oxygen and the rate of catalysis, than might be the case with 
other types of enzyme.
In vitro studies of the kinetic behavior of recombinant HIF 
hydroxylases have indicated that both the PHDs and FIH 
can operate as high turnover enzymes, with a maximum rate 
of enzymatic metabolism (V
Max
) in the range of 50–200 mol/
mol/min33–35. Such studies have also defined apparent 
Michaelis constant (K
m
) values for Fe(II), ascorbate, 2-OG, 
and oxygen. In keeping with predictions from kinetic analy-
ses of other members of the 2-OG oxygenase superfamily 
that it is an E.2-OG substrate species that interacts with 
molecular oxygen, the apparent K
mO2
 varies with the HIF 
polypeptide substrate used in the assay36,37. Thus, for short 
HIF polypeptides in the range 15–30 residues, K
mO2
 values 
of approximately 200 µM have been measured for the PHDs 
whilst measurements using HIF polypeptides in the range 
of 150–250 residues have yielded values of approximately 
80–100 µM. All these values are well above measured tissue 
pO
2
, and (given that oxygen is not produced by animal cells) 
they can be predicted to be above the concentration avail-
able to the enzymes within their subcellular compartment. 
Thus, the availability of oxygen is predicted to be limiting for 
activity over the entire physiological range—fulfilling a con-
dition for their operation as oxygen sensors.
HIF hydroxylase co-factors also appear to be limiting for 
catalytic activity under physiological or pathophysiological 
conditions, and thus act to modulate the “oxygen sensing” 
function.
Lability of iron-binding accounts for the classical prop-
erty of the HIF system of being activated by iron chela-
tion as well as hypoxia. Tissue culture cells, especially 
rapidly growing cells with activated oncogenic pathways, 
accumulate HIF in a non-hydroxylated form even under 
well-oxygenated conditions38,39. Addition of iron (or ascor-
bate) to such cells promotes HIF prolyl hydroxylation 
and down-regulates HIF, suggesting that iron, ascorbate, 
or both are limiting under these conditions39,40. The extent 
of which iron/ascorbate limitation of HIF hydroxylation 
occurs physiologically in vivo is of substantial interest. 
For instance, human studies of pulmonary responses to 
hypoxia have recently demonstrated not only that infusions 
of iron chelators can mimic responses to hypoxia but also 
that iron infusions to apparently normal subjects can blunt 
responses to hypoxia41. Whether the observed effects are in 
fact mediated by effects on HIF hydroxylases is not proven, 
but taken together with the cell culture studies, the findings 
raise the possibility that physiological changes in cellular 
availability of iron, as well as oxygen, may modulate these 
pathways. Given the frequency of clinical iron deficiency, 
particularly in malignant disease, this is now an important 
avenue for further investigation.
The HIF hydroxylase co-substrate 2-OG plays a pivotal 
role in metabolism. It is a Krebs cycle intermediate that is 
a substrate for nicotinamide adenine dinucleotide (NAD)-
linked oxidation by -ketoglutarate (2-OG) dehydrogenase, 
a co-substrate/product in (reversible) reductive amination/
oxidative deamination by glutamate dehydrogenase, and the 
major amino group acceptor for transaminases. In addition, 
the HIF hydroxylases have been reported to be inhibited by 
citrate, isocitrate, succinate, fumarate, malate, oxaloacetate, 
and pyruvate42–46. For at least some of these metabolites, 
in vitro kinetic studies have indicated that they act by com-
petitive inhibition of 2-OG binding. Given the difficulties 
of measurement of these metabolites in different intracel-
lular compartments (e.g. cytosolic versus mitochondrial), 
the effects of altered intermediary metabolism in vivo are 
difficult to predict from these data. Nevertheless, the pos-
sibility that hydroxylase co-substrate requirements for both 
molecular oxygen and 2-OG link oxygen and “metabolic” 
sensing is appealing.
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8  Peter Ebbesen et al.
Both succinate dehydrogenase (SDH) and fumarate 
hydrate (FH) have been identified as tumor suppressors. 
In SDH- and FH-associated cancer, intracellular accu-
mulation of succinate and fumarate results in impair-
ment of HIF hydroxylation44,47. The resultant increase in 
HIF can be reduced by extracellular provision of esteri-
fied (cell penetrating) 2-OG48. Taken together with in vitro 
kinetic data demonstrating competitive inhibition of PHD 
enzymes by fumarate and succinate, these findings indi-
cate that at least under these conditions, fumarate and 
succinate act as endogenous modulators of HIF 
hydroxylase activity43,45. Whether this can occur in 
other situations in which the Krebs cycle is inhibited, and 
whether 2-OG is itself limiting under other conditions, are 
unclear.
Overall, these findings have brought into focus two 
important considerations in relation to the work of the 
EUROXY consortium. First, they raise the possibility that 
therapeutic interventions might be targeted at increasing, 
as well as reducing, HIF hydroxylase activity and suggest 
that the clinical importance of iron/ascorbate status and 
metabolic energy provision in cancer patients should be 
re-evaluated40,49–51. Second, they provide potential insights 
into the mechanisms by which a wide range of redox active 
stimuli that do not appear to affect the cellular avail-
ability of oxygen directly may impact on the regulation of 
HIF52,53.
As is detailed elsewhere in the cited references, a range 
of genetic and pharmacological interventions that affect the 
intracellular production of reactive oxygen species (ROS) 
modulate the HIF system54–57. Accumulating data indicate 
that many of these interventions affect HIF hydroxylase 
activity. Possible modes of action include direct effects on 
the HIF hydroxylase catalytic center, effects on ascorbate/
dehydroascorbate and Fe(II)/Fe(III) redox couples, effects 
on the Krebs cycle through ROS-mediated inactivation of 
susceptible enzymes such as aconitase, or effects on the 
many NAD-linked or nicotinamide adenine dinucleotide 
phosphate (NADP)-linked redox couples that could directly 
or indirectly affect 2-OG availability.
Though obstacles remain, particularly in the measure-
ment of relevant metabolites within appropriate subcellu-
lar compartments, and in the accurate measurement of the 
extent of hydroxylation at specific sites in HIF polypeptides, 
these advances provide a new framework for understand-
ing biological responses to hypoxia and how they might be 
manipulated in cancer and other diseases.
4.2. Pre-mRNA splicing
The coding regions (exons) of most human genes are inter-
rupted by non-coding intervening sequences (introns) 
that are removed from pre-mRNA molecules to pro-
duce mature mRNAs through the process of RNA splic-
ing. RNA splicing takes place in the nucleus and occurs 
co-transcriptionally58,59.
Exons are defined by rather short and degenerate classi-
cal splice-site sequences at the intron/exon borders (5’ splice 
site, 3’ splice site, and branch site) (Figure 3). Components of 
the basal splicing machinery bind to the classical splice-site 
sequences and promote assembly of the multicomponent 
splicing complex known as the spliceosome. Intron removal 
must be performed with the precision of up to one nucle-
otide. The spliceosome performs the two primary functions 
of splicing: recognition of the intron/exon boundaries and 
catalysis of the cut-and-paste reactions that remove introns 
and join exons58,59.
The spliceosome is made up of five small nuclear ribo-
nucleoproteins (snRNPs) and > 100 proteins. Each snRNP 
is composed of a single uridine-rich small nuclear RNA 
(snRNA) and multiple proteins. The U1 snRNP binds the 
5’ splice-site, and the U2 snRNP binds the branch site via 
RNA:RNA interactions between the snRNA and the pre-
mRNA. Spliceosome assembly is highly dynamic. However, 
it is not fully understood how it is accomplished58,59.
The typical human gene contains an average of eight 
exons. Internal exons average 145 nucleotides in length, 
and introns average more than 10 times this size and can be 
much larger. Alternative splicing pathways generate different 
mRNAs encoding distinct protein products, thus increasing 
the coding capacity of genes. Recent genome-wide analyses 
of alternative splicing indicate that up to 70% of human 
genes may have alternative splice forms, suggesting that 
alternative splicing together with various post-translational 
modifications plays a major role in the production of prote-
ome complexity60.
Pre-mRNA splicing is a sophisticated and ubiquitous 
nuclear process, which is a natural source of cancer-
causing errors in gene expression. Changes in splice-site 
selection have been observed in various types of cancer, 
and may affect genes implicated in tumor progression and 
in susceptibility to cancer61. In cancer, there are examples 
of every kind of alternative splicing, which include the use 
of alternative individual splice sites, alternative exons, and 
alternative introns. Splicing changes have been observed 
in genes implicated in both the susceptibility and the 
progression of cancer (oncogene KIT, neurofibromatosis 
type 1 (NF1) protein, rac1, oncogene crk, Kruppel-like 
Zn finger transcripion factor KLF6, androgen receptor, 
sex hormone-binding globulin, DNA methyltransferase 
DNMT3b, nucleocytosolic adapter protein Bin1). The 
mechanisms leading to splicing defects in cancer are 
poorly understood62–65.
3' splice
site
5' splice
site
Figure 3. Elements involved in alternative splicing of pre-mRNA. Exons 
are indicated as boxes, introns as thin lines. The 5’ splice-site (CAGguaagu) 
and 3’ splice-site cagG, as well as the branch point (ynyurac) and polypy-
rimidine tract (yyyyy), are indicated (y: c or u, n: a, g, c, or u, r: a or g). 
Upper case letters refer to nucleotides that remain in the mature mRNA.
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Hypoxia has long been recognized as a common feature 
of solid tumors and a negative prognostic factor for response 
to treatment and survival of cancer patients. The discovery 
of HIF-1, a molecular determinant of the response of mam-
malian cells to hypoxia, has led to the identification of a 
“molecular target” of hypoxia suitable for the development 
of cancer therapeutics66,67.
It has been demonstrated that in mice the protein IPAS 
(inhibitory PAS protein), a dominant negative regulator 
of hypoxia-inducible gene expression, is generated from 
HIF-3 pre-mRNA by an alternative splicing mechanism. 
At normal atmospheric oxygen tension, IPAS expression 
is restricted (in mice) to the avascular cornea epithelium. 
Inactivation of the IPAS transcript leads to neovasculariza-
tion of the cornea, suggesting that IPAS is an important 
mechanism of anti-angiognenesis in this tissue. Strikingly, 
IPAS mRNA expression is induced in heart and lung tissue 
samples from hypoxic mice68. IPAS expression in hepatoma 
cells selectively impairs the induction of hypoxia-inducible 
genes regulated by HIF-1 and results in retarded tumor 
growth and tumor vascular density in vivo. In mice, IPAS 
was selectively expressed in Purkinje cells of the cerebel-
lum and in the corneal epithelium of the eye. Moreover, the 
expression of IPAS in the cornea correlates with low vascular 
endothelial growth factor (VEGF) gene expression under 
hypoxic conditions68.
Recently in mice, another hypoxia-inducable negative 
regulator NEPAS (neonatal and embryonic PAS protein) 
was found69. Its mRNA, as in the IPAS case, derives from 
the HIF-3 gene by alternative splicing, where the first exon 
of HIF-3 is replaced with the IPAS first exon. NEPAS can 
dimerize with Arnt, and shows only low levels of transcrip-
tional activity. NEPAS is expressed in the late embryonic 
and early postnatal stages and its expression is predominant 
in the lung and heart. It is reported that NEPAS suppresses 
gene expression driven by HIF-1 and HIF-269.
In addition, multiple HIF -subunit isoforms, generated 
by alternative pre-mRNA splicing and expressed in different 
tissues, have been identified in humans70–72. For instance, 
three isoforms have been identified for HIF-1 protein: the 
HIF-1827 (at exon 1–2 junction containing an additional 
arginine residue), HIF-1736 (lacking exon 14), and HIF-
1516 (lacking exons 11 and 12) isoforms. It has been shown 
that the HIF-1736 isoform is three-fold less active compared 
to the full length HIF-1 protein, and the HIF-1516 isoform 
suppresses hypoxic induction of HIF-1-regulated genes. All 
these isoforms are ubiquitously expressed in mammalian 
tissues. Also, five additional HIF-3 protein isoforms gen-
erated by alternative pre-mRNA splicing (HIF-32 (also 
referred to as human IPAS), HIF-33, HIF-34, HIF-35, 
HIF-36) have been identified72. It has been suggested that 
some of these isoforms can act as negative HIF-1 function 
regulators.
In conclusion, alternative splicing of the mouse HIF-3 
locus generates NEPAS and IPAS mRNA species which appear 
to be tissue-specific and strictly regulated by hypoxia, defin-
ing a novel mechanism of hypoxia-dependent regulation of 
gene expression69,73. In tumors this mechanism is an attrac-
tive means to target HIF signaling.
Also, recently, a truncated isoform of human cancer-
associated CA IX, lacking part of the catalytic domain, was 
discovered. It has been shown that the shorter CA IX isoform 
is produced from the same pre-mRNA as the long one, by an 
alternative pre-mRNA splicing. The short CA IX isoform is 
detectable in normal tissues, while the long CA IX isoform is 
detectable only in hypoxic tissues74. The appearance of the 
long CA IX isoform only in hypoxic cells indicates that CA 
IX pre-mRNA splicing is strictly regulated by cellular oxygen 
tension.
Cancer is a multistep process that involves severe 
changes in gene expression. The more we learn about regu-
latory pathways that are disturbed during tumorigenesis, the 
more we realize about the complexity of tissue homeostasis. 
Thus, elucidation of the molecular mechanisms of regula-
tion of RNA processing by oxygen tension is critical for our 
understanding of the biology of these important regulatory 
proteins, in particular our understanding of their role in ang-
iogenetic and tumorigenic processes.
4.3. Transcription and regulators at moderate hypoxia
Activation of transcription in response to low oxygen 
tension is mediated by the hypoxia-inducible factors 
(HIFs) 1–3. These transcription factors are heterodimeric 
complexes of two proteins: Arnt, which is constitutively 
expressed, and HIF proteins 1–3, the stability and trans-
activation function of which are regulated by oxygen 
levels. In the HIF proteins 1–2 there are two functional 
domains mediating transcriptional activation by interac-
tion with transcriptional co-regulatory proteins and the 
transcriptional machinery. One of these two domains, the 
N-terminal transactivation domain (N-TAD), is located 
within the oxygen-regulated degradation domain, whereas 
the other transactivation domain, termed C-terminal acti-
vation domain (C-TAD), is located in the very C-terminus 
of the HIF proteins 1–2.
CREB binding protein (CBP)/p300 is the major tran-
scriptional co-regulatory factor participating in HIF-1-
dependent activation of transcription. The C-terminal 
activation domains (C-TADs) of both HIF-1 and HIF-2 
have been shown to interact with the cysteine/histidine-rich 
region 1 (CH1) of CBP/p300 in a hypoxia-dependent man-
ner. Within the EUROXY program we have demonstrated 
that the N-terminal activation domain (N-TAD) of either 
HIF-1 or HIF-2 is also able to interact with endogenous 
CBP, and that this interaction facilitates the transactivation 
function of the corresponding HIF complexes.
The HIF protein 3 distinguishes itself from the HIF pro-
teins 1–2 by only having the N-TAD and not the C-TAD. Thus, 
HIF-3 also shows both oxygen-regulated protein stability 
and transactivation function but is a much weaker transacti-
vator than HIF proteins 1–2. This property of HIF-3 results 
in it being a negative regulator of the hypoxia-dependent 
gene regulatory response when HIF-3 is in excess over 
HIF-1 or HIF-2.
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We have observed in neuroblastoma tumor cells that 
HIF-1 stabilization under hypoxic (1% oxygen) condi-
tions is primarily an acute response to hypoxia, and that 
HIF-1 protein levels become reduced or disappear at pro-
longed hypoxia. HIF-2 levels, on the other hand, continue 
to increase with time at hypoxia, and we have observed 
that hypoxia-driven genes, primarily VEGF, are a HIF-1 
target during an acute phase, while HIF-2 becomes more 
important as an activator of VEGF gene expression during 
later phases of hypoxia. Based on our observations in neu-
roblastoma, HIF-1 and HIF-2 seem to have the capacity 
to transcribe most of the hypoxia-driven genes containing 
HRE sequences, but they do it in different contexts, for 
instance as a response to acute or prolonged hypoxia. Thus, 
the question of what genes are driven by either of the HIFs 
might simply be answered by a lack of target gene prefer-
ences and that the HIF dependence instead is context-
dependent.
There is a clear link between hypoxia and regulation of 
the cell differentiation status. We have previously observed 
that hypoxia induces dedifferentiation of neuroblastoma 
tumor cells. In this process there is a clear integration 
between the HIF and Notch signaling pathways to medi-
ate the hypoxia-dependent dedifferentiation process. In 
addition to this mode of regulation, hypoxia promotes the 
undifferentiated cell state in various stem and precursor 
cell populations. We have also shown that the latter proc-
ess requires Notch signaling. Hypoxia blocks neuronal 
and myogenic differentiation in a Notch-dependent man-
ner. Hypoxia activates Notch-responsive promoters and 
increases expression of direct Notch downstream genes. 
The Notch intracellular domain interacts with HIF-1, 
and HIF-1 is recruited to Notch-responsive promoters 
upon Notch activation under hypoxic conditions. Taken 
together, these data provide molecular insights into how 
reduced oxygen levels control the cellular differentiation 
status and demonstrate a role for both HIF-1 and Notch 
in this process. We are now exploring whether regulation of 
the tumor cell differentiation status by the integrated HIF/
Notch signaling pathways is a relevant new target for tumor 
therapy.
4.4. Targeting tumor hypoxia through interference with 
mTOR and the UPR signaling
4.4.1. Introduction
Mammalian cells utilize multiple mechanisms to adapt 
to changes in nutrient supply, energy, and oxygen75. Often 
these mechanisms are exploited by tumor cells in order to 
survive the harsh conditions that exist within the microen-
vironment of solid human tumors76. The ability to adapt to 
hypoxia seems particularly important, as high levels of tumor 
hypoxia are associated with poor patient prognosis77. This 
adaptation influences the behavior of tumor cells by activat-
ing a number of oxygen-sensitive pathways that have been 
reviewed recently78. Of these, the best understood pathway 
is mediated by the HIF family of transcription factors. More 
recently, two other oxygen-sensitive pathways have been 
described that mediate changes in gene expression and 
important phenotypic tumor traits.
4.4.2. The role of mTOR signaling during hypoxia
The first of these newly identified pathways is regulated 
through the mammalian target of rapamycin (mTOR) kinase 
and its downstream effectors that coordinate processes 
such as the initiation of protein synthesis, autophagy, and 
apoptosis. Activity of mTORC1 is inhibited under moderate 
hypoxia (~1% O
2
), resulting in decreased protein synthesis 
and proliferation in cells of benign origin79–81. Severe hypoxia 
(≤ 0.1% O
2
) on the other hand inhibits mRNA translation in 
nearly all cell types82. Since protein synthesis is extremely 
adenosine triphosphate (ATP)-costly, this inhibition in 
mRNA translation may be essential in order to maintain the 
energy balance within the cell. Nevertheless, it is currently 
unclear to what extent mTORC1 inhibition is accountable 
for the translational repression that is observed under severe 
hypoxia.
Part of this translational repression is mediated through 
dephosphorylation of one of the mTORC1 downstream 
effectors, 4E binding protein 1 (4E-BP1). Initiation of cap-
dependent mRNA translation requires binding of the eIF4F 
complex to the 59 cap structure of the mRNA. This complex 
consists of the cap-binding protein eIF4E, the scaffolding 
protein eIF4G, and the RNA helicase eIF4A. During hypoxia, 
4E-BP1 becomes hypophosphorylated and scavenges eIF4E 
away from eIF4G, thereby preventing initiation of cap-de-
pendent mRNA translation. We have shown that knockdown 
of 4E-BP1 by overexpression of a shRNA against 4E-BP1 
does not noticeably alter the overall inhibition of transla-
tion in cancer cells during severe hypoxia83. Nevertheless, 
4E-BP1 does play an important role by modulating mRNA 
translation of specific genes83. Interestingly, we observed 
an increased sensitivity to hypoxia for the 4E-BP1 depleted 
cancer cells in clonogenic assays (Magagnin et al., unpub-
lished results). Xenograft tumors established from 4E-BP1 
deficient cells did not demonstrate any difference in overall 
tumor growth or in their hypoxic fraction (determined by 
pimonidazole) as compared with their wild-type controls. 
However the 4E-BP1 deficient tumors showed increased 
cell death in hypoxic regions and had decreased ATP lev-
els compared with controls. This might explain the notable 
differences in radiosensitivity that we observed after single 
dose irradiation of 10 Gy. Xenograft tumors derived from 
4E-BP1 knock-down cells required a significantly longer 
time to reach the initial tumor starting volume after irra-
diation (Magagnin et al., unpublished results). These data 
suggest that control of translation through 4E-BP1 acts as 
an important metabolic brake to preserve cell survival in 
tumors, resulting in an increased number of viable radiore-
sistant hypoxic cells.
The fact that hypoxia can influence mTOR signaling and 
cap-dependent translation has potential implications for 
the use of a number of new agents that are directed against 
these pathways, including rapamycin. Our data suggest that 
these drugs may influence hypoxia tolerance, or at least 
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be differentially effective against hypoxic cells. In support 
of this idea, we recently showed that although rapamycin 
causes a substantial tumor growth delay on its own, it does 
not improve the ability to cure tumors with fractionated 
radiotherapy84.
4.4.3. Hypoxia and the unfolded protein response
The second oxygen-sensitive signaling pathway involves 
activation of the unfolded protein response (UPR). This is 
a program of transcriptional and translational changes that 
occur as a consequence of endoplasmic reticulum (ER) 
stress. Three distinct ER-stress sensors initiate the UPR: 
PERK, IRE1, and ATF6. PERK is activated upon hypoxia, 
resulting in phosphorylation of its main substrate eIF2 on 
serine residue 51. This is a rapid but reversible response that 
occurs within minutes when cells encounter severe hypoxic 
conditions and takes somewhat longer under more moder-
ate oxygenation conditions (1%)85. Phosphorylation of eIF2 
upon hypoxia has been shown in a diverse panel of cell lines 
from either normal or neoplastic tissue82,85. PERK activa-
tion and subsequent downstream signaling is important 
for survival during hypoxic conditions82,85. PERK knock-out 
mouse embryonic fibroblasts (MEFs) revealed increased 
hypoxia sensitivity and profoundly decreased tumor growth 
compared to their wild-type controls in xenograft studies86. 
Reduced hypoxia tolerance was also observed after disrup-
tion of PERK signaling by other means, such as expression of 
unphosphorylatable eIF2 (S51A), dominant negative PERK, 
or overexpression of eIF2 phosphatase GADD3482,85.
4.4.4. Changes in gene expression through regulation  
of translation
Hypoxic signaling through mTOR and the UPR both con-
tribute to changes in gene-specific mRNA translation during 
hypoxia78,87–89. Together with the transcriptional program 
mediated by HIF this regulation mediates important changes 
in protein expression that influence cell behavior in hypoxic 
tumors. Importantly, mTOR and UPR affect different subsets 
of genes compared to the well known transcriptional targets 
of the HIF pathway. This opens up new opportunities for 
the discovery of novel diagnostic and therapeutic targets in 
 hypoxic cells.
To obtain better insight into the contribution of trans-
lational control on hypoxia-induced gene expression, we 
performed a microarray study to assess both transcriptional 
and translational changes when cells are exposed to hypoxia 
(van den Beucken et al., unpublished data). Both total RNA 
and efficiently translated mRNA were extracted from DU145 
human prostate carcinoma cells after exposure to hypoxia 
for different lengths of time (0, 1, 2, 4, 8, 12, 16, and 24 hours). 
Expression profiles were determined for genes regulated 
either at the transcriptional (total RNA) or the translational 
(polysomal RNA > 5 ribosomes) level using Affymetrix tech-
nology. This study demonstrated that translational control 
significantly affects both hypoxia-induced and -repressed 
genes at all time points examined. The contribution is most 
pronounced during acute hypoxia (2–4 h), as the influence 
of transcription becomes more important after prolonged 
hypoxia. Our data indicate that translation influences gene 
expression during hypoxia on a scale comparable to that of 
transcription, and reveals many potentially interesting tar-
gets for diagnosis and/or therapy.
Translational regulation of one of the identified genes, 
Cited2, was characterized in more detail89. Our data provide 
further evidence that Cited2 can antagonize the interaction 
between HIF-1 and its co-activator CBP/p300, and thus is 
able to prevent HIF-1 transcriptional activation. These data 
also suggest that substantial cross-talk exists between tran-
scriptional and translational cellular response programs89.
During our gene expression profiling studies we also 
discovered that induction of the HIF-regulated gene CA IX 
was severely compromised in cells derived from an eIF2 
S51A knock-in mouse89. This finding was reproduced in 
two isogenic human tumor cell lines that were defective for 
eIF2 activation. The underlying mechanism for this defect 
involved direct binding of the eIF2-dependent translation-
ally regulated gene ATF4 to the CA IX promoter. Furthermore, 
we were able to show that transcriptional activation of the CA 
IX promoter was associated with loss of the transcriptional 
repressive histone 3 lysine 27 (H3K27) tri-methylation mark. 
In xenograft studies, eIF2 activation impaired U373 cells 
and showed CA IX protein levels comparable to those in HIF 
knock-down cells. This study reveals that CA IX expression 
is mediated through independent activation of both the HIF 
and eIF2 phosphorylation. These data may have impor-
tant implications for the use of CA IX as a diagnostic tumor 
marker or molecular drug target (unpublished results)89.
Oxygen levels in human tumors are not static. Changes 
in blood flow result in periodic changes in oxygenation 
within a large fraction of the tumor. Exposure to cycles of 
hypoxia and reoxygenation causes different kinds of cellular 
stress, and therefore likely requires different stress response 
mechanisms. Using a proteomic approach we investigated 
changes in protein expression in tumor cells after reoxygen-
ation90. We successfully identified several proteins, includ-
ing ribosomal protein P0, valosin-containing protein (VCP), 
and FUSE binding protein 2, which are involved in different 
cellular processes such as protein synthesis and degrada-
tion. Interestingly, VCP, which is involved in ER-associated 
degradation (ERAD), translocates from the nucleus to the 
cytoplasm upon reoxygenation90. This contributes to the 
removal of potentially toxic misfolded proteins that accu-
mulate during transient periods of hypoxia. Together, this 
study suggests that these newly identified proteins might 
contribute to the recovery of ER stress and protein synthesis 
during reoxygenation90. Subsequently these proteins may 
thus be important determinants of survival after transient 
exposures to hypoxia.
4.4.5. Conclusions
In summary, the HIF, mTOR, and UPR pathways play 
important roles in determining the hypoxic cell phenotype, 
hypoxia tolerance, and tumor growth. Integral components 
or downstream targets of these oxygen-sensitive pathways 
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have potential interest as either direct targets for therapy or 
as novel diagnostic markers for tumor hypoxia. In the future 
it will be important to further evaluate which of these path-
ways contributes most to the adverse phenotype and poor 
prognosis associated with hypoxia in human tumors.
4.5. Importance of ROS signaling in tumors
Oxygen free radicals such as superoxide anion and other 
reactive oxygen species (ROS) are derived from electron 
transfer on molecular oxygen. ROS have the potential, due to 
their oxidizing properties, to damage proteins, nucleic acids, 
and lipids, and thus have been considered for a long time 
as harmful agents. Indeed, ROS derived from exogenous 
sources such as toxins, radiation, UV light, and metals have 
been implicated in the development of cancer, in particular 
due to their damaging effects on DNA91.
However, ROS production is a genuine function of all 
aerobic cells. In fact, ROS are continuously produced in 
aerobic organisms as by-products of normal energy metab-
olism. During aerobic metabolism, electrons can escape 
from the mitochondrial electron transport chain, especially 
complexes I and III, and react with molecular oxygen to 
form the superoxide radical. This superoxide radical is then 
converted into hydrogen peroxide by superoxide dismutase 
2 (SOD2). Whereas complete deficiency of SOD2 is embry-
onically lethal, the incidence of certain tumors has been 
shown to increase 100% in old heterozygous SOD2 mice 
compared with wild-type mice92. In a liver-specific SOD2 
knock-out model, early signs of liver cell transformation 
were observed93.
A key feature of many tumor cells is their increased need 
for a high amount of energy to support their increased rate 
of cellular activity. Thus, the neoplastic phenotype of many 
tumors has been associated with an increased production of 
ROS. As superoxides are constantly produced during respi-
ration, and are converted into other ROS, mitochondria are 
considered an important source of cellular ROS in cancer94.
It has also been demonstrated in some cancers that the 
increased levels of ROS produced during the increased 
energy demands of a tumor can directly mutate the mito-
chondrial genome. Mitochondrial DNA appears to be highly 
susceptible to mutagenic ROS not only due to its close prox-
imity to their source, but also due to the fact that the mito-
chondrial genome does not contain non-coding sequences. 
Thus, mitochondrial proteins may be synthesized that are 
not as efficient at containing the electrons during ATP pro-
duction in the respiratory chain, contributing to increased 
ROS production in the mitochondrion95.
In addition to mitochondria, a variety of enzymes are able 
to use molecular oxygen to generate ROS. In fact, low levels 
of ROS generated in response to distinct signals including 
growth factors, cytokines, hormones, coagulation factors, 
and other growth promoting agents have been implicated 
to act as cellular signals promoting proliferation of cells96–98. 
Thus, ROS signaling may be of major importance not only 
for tumor initiation and carcinogenesis, but also for tumor 
growth and progression.
Important targets of ROS are  the iron  protein tyrosine 
phosphatases, which can be oxidized by the iron ROS at 
specific cysteines, thus modulating their activity99. In fact, 
ROS have been shown to increase the activity of a variety of 
kinases including mitogen-activated protein (MAP) kinases 
and Akt, which have been considered to stimulate tumor 
growth, prevent apoptosis, and enhance survival. In addi-
tion, important transcription factors including nuclear factor 
B (NFB), and activator protein 1 (AP1), which are known 
to be associated with cancer development, are regulated by 
ROS100. Recently, HIFs, which promote tumor growth under 
hypoxic conditions, have been recognized to be induced and 
activated by ROS also under non-hypoxic conditions101,102. 
Moreover, HIF-1 has been shown to be a transcriptional 
target of NFB103,104. These findings open new avenues in our 
understanding of tumor cell growth and therapeutic sensi-
tivity by linking hypoxia signaling with ROS signaling.
The notion that ROS can act as signaling molecules indi-
cates that ROS should be generated in a controlled manner. 
Several enzymes have been associated with receptor-con-
trolled ROS productions In this regard, NADPH oxidases 
have gained increasing attention. These enzymes catalyze 
the NADPH-dependent reduction of molecular oxygen to 
the superoxide radical. NADPH oxidases comprise a fam-
ily of multiprotein enzymes consisting of transmembrane 
proteins called Nox proteins and the p22phox subunit and 
several regulatory cytoplasmic proteins including p47phox 
and p67phox and their homologs NoxO1 and NoxA1, as 
well as p40phox and the GTPase Rac-1. The Nox family of 
proteins consists of seven members (Nox1, Nox2, Nox3, 
Nox4, Nox5, DUOX1, and DUOX2). They all share a similar 
structure, with a six-transmembrane domain, a NADPH 
binding domain, and a cytoplasmic domain. Each member 
is differentially expressed in different tissues, and is regu-
lated in different ways. As a consequence they have been 
suggested to serve different biological functions, although 
the exact role of each Nox is far from being elucidated105. 
Interestingly, Nox proteins have been found in several can-
cer forms and transformed cells, as f.e. in gastrointestinal 
tumors. However, this expression did not correlate strictly 
with the normal tissues, suggesting that Nox expression 
could be deregulated during carcinogenesis106. NADPH 
oxidases have been shown to be important sources of 
ROS in various signaling cascades. They have been associ-
ated with the activation of different kinases in various cell 
types, among them the PI3 kinase/Akt pathway. Moreover, 
NADPH oxidases have been shown to regulate transcrip-
tion factors important for tumor progression, including 
NFB and AP1. Strikingly, NADPH oxidases can also 
regulate HIF levels and HIF activity, thus linking them 
intimately to hypoxia signaling and sensitivity to thera-
pies. Thus, increased Nox signaling may be of importance 
for permitting survival signals during tumorigenesis, and 
could be involved in signaling processes relevant to tumor 
formation and progression102.
In addition, evidence has been accumulated that ROS and 
NADPH oxidases are also involved in the formation of new 
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vessels (angiogenesis), a process which is highly relevant for 
tumor growth and therapeutic sensitivity97,107.
However, tumor vessels are clearly distinct from func-
tional normal vessels, and perfusion can be irregular or even 
absent. Thus, the tumor microenvironment is characterized 
by episodes of cycling hypoxia and fluctuating ischemia and 
reperfusion, events which have been intimately linked to 
enhanced ROS levels and NADPH oxidase activity in vari-
ous ischemic disorders108,109. Although the exact importance 
of cyclic hypoxia and ischemia–reoxygenation for tumor 
progression and therapeutic sensitivity is not clear at the 
moment, initial studies suggest an important role of these 
events and thus ROS in tumor survival and therapeutic 
sensitivity110.
Finally, the tumor microenvironment is characterized by 
the invasion of inflammatory cells, which are intrinsically 
able to generate ROS via the leukocyte NADPH oxidase111,112. 
Thus, cells within a tumor may also be exposed to exog-
enous ROS. Several studies in vitro implicated that exog-
enous application of ROS such as H
2
O
2
 can activate kinase 
pathways, HIF and other transcription factors, proliferation, 
and angiogenesis52,113,114. Thus, leukocyte-derived ROS may 
 represent an additional way to activate cellular signaling cas-
cades by ROS in tumor cells and to modify tumor growth.
Taken together, activated oxygen species generated in 
tumor cells and different tumor-associated cells under dif-
ferent microenvironmental conditions play an important 
role in tumor initiation, tumor progression, and therapeutic 
sensitivity. Thus, therapeutic strategies targeting tumor cells 
in their ever changing microenvironment will need to take 
ROS as drug targets into account.
4.6. pH Regulation at the cellular and tissue level
Inadequate oxygen delivery to hypoxic tumor regions 
restricts oxidative phosphorylation and limits energy pro-
duction. Therefore, hypoxic tumor cells shift their metabo-
lism toward glycolysis, which is less efficient in energy yield 
but does not depend on oxygen. However, glycolysis often 
sustains after reoxygenation, because its metabolic inter-
mediates can be utilized for biosynthesis of certain amino 
acids, nucleotides, and lipids, providing selective advantage 
to proliferating tumor cells. This explains classical Warburg’s 
observation of high glucose consumption and high lactate 
production in tumor tissues115.
Lactate is the principal end product of glycolysis, but the 
oncogenic metabolism also generates an excess of protons 
and carbon dioxide116,117. Tumor cells eliminate these acidic 
catabolites in order to preserve neutral intracellular pH (pHi) 
that is optimal for cell proliferation and survival118. Lactate 
and protons are extruded by ion transporters and pumps 
including the H+/monocarboxylate transporter (MCT), the 
Na+/H+ exchanger (NHE), and the vacuolar H+/ATP pump. 
Acid export leads to a reduction of extracellular pH (pHe) 
that is typical for the tumor microenvironment. In addition, 
bicarbonate transporters, such as anion exchangers (AEs) 
and Na+/bicarbonate co-transporters (NBCs), import bicar-
bonate ions to cytoplasm where they react with protons and 
increase cellular production of CO
2
. This reaction consumes 
intracellular protons contributing to pHi neutralization, and 
CO
2
 diffuses to pericellular space, further reducing pHe, as 
illustrated in Figure 4. The resulting microenvironmental 
acidosis has important biological consequences, including 
up-regulation of angiogenic factors and proteases, increased 
invasion, and impaired immune functions, and thereby 
contributes to tumor progression. Moreover, acidosis can 
modulate the uptake of anti-cancer drugs and modify the 
outcome of conventional therapy119.
One of the mechanisms that enable hypoxic tumor cells 
to adapt to an acidic microenvironment involves a tumor-
associated hypoxia-induced carbonic anhydrase IX, which is 
a direct transcriptional target of HIF and belongs to strongly 
hypoxia-dependent proteins120. CA IX is the member of a 
carbonic anhydrase (CA) family of enzymes that catalyze 
the reversible hydration of carbon dioxide to carbonic acid 
and participate in acid–base balance121. The 15 human 
CA isoforms are expressed at variable levels and differ by 
activity and kinetic properties, and subcellular and tissue 
Figure 4. pH regulation in hypoxic tumor cells. Hypoxia triggers a 
 metabolic shift to glycolysis via HIF-induced up-regulation of glucose 
transporters (mainly GLUT1) and glycolytic enzymes. Glycolysis pro-
duces an excess of lactate and protons that have to be exported out of 
the cell to prevent intracellular acidification that is incompatible with 
cell growth and survival. This extrusion is executed by the monocarboxy-
late transporter (MCT1 and 4) and the Na+/H+ exchanger (NHE1), both 
transcriptionally regulated by HIF. Acidic catabolites are accumulated in 
the extracellular microenvironment and cause extracellular acidosis that 
supports invasion. However, oncogenic metabolism also produces a high 
amount of CO
2
 that diffuses through the plasma membrane and contrib-
utes to extracellular acidosis. Hypoxia-induced transmembrane carbonic 
anhydrase CA IX (and CA XII) catalyze a CO
2
 conversion to bicarbonate 
ions and protons. Bicarbonate ions are taken by bicarbonate transport-
ers (BTs) and imported to intracellular space where they contribute to 
neutralization of intracellular pH. Protons remain outside of the cell and 
further acidify the microenvironment.
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distribution. They are mostly associated with differentiated 
cells of normal tissues, except CA XII that is elevated in some 
tumor types, and CA IX, which is predominantly expressed 
in diverse solid tumors including carcinomas of kidney, 
head and neck, lung, breast, uterine cervix, etc.122.
CA IX is a transmembrane protein whose catalytic site 
faces the extracellular space and accelerates the pericellular 
metabolism of CO
2
 in a spatial and functional cooperation 
with bicarbonate transporters123,124. CA IX produces bicar-
bonate ions, which are actively transported to cytoplasm by 
bicarbonate transporters and contribute to neutralization 
of intracellular pH. In the same reaction, it also generates 
protons that remain in extracellular space and contribute 
to pericellular acidosis (Figure 4). Functional involvement 
of CA IX in pH regulation in hypoxic cells has recently been 
demonstrated using cell models with ectopic expression of 
CA IX125–127.
It has also been shown that hypoxia activates the cata-
lytic performance of CA IX and that inhibitors of CA activity 
bind to hypoxic, but not to normoxic cells125,128. On this basis 
it has been proposed that CA inhibitors can be potentially 
utilized for imaging of actually hypoxic tumors, in contrast 
to CA IX-specific monoclonal antibodies that visualize CA IX 
protein independently of hypoxia. Because CA IX is a stable 
protein (with a half-life of about 38 h), the antibodies detect 
both present and past hypoxia129. In that sense, inhibitors and 
antibodies might provide different prognostic information.
4.7. Cellular metabolism and respiration
A common feature of most malignant cells is their unique 
adaptation to the hypoxic tumor microenvironment, most 
obviously by angiogenesis and apoptotic resistance75. 
Another important strategy adopted from physiological 
hypoxia acclimatization is the alignment of oxygen avail-
ability with cellular metabolism, in particular by switching 
to anaerobic glycolysis, lowering energy-consuming proc-
esses such as protein synthesis, and adjusting mitochondrial 
respiration. In contrast to physiology, the glycolytic switch 
is often permanent, known as “aerobic glycolysis” or the 
Warburg effect, and kept up even when tumor cells are cul-
tivated for a long time under oxygen excess conditions, sug-
gesting (epi)genetic selection for hypoxia-tolerant cancer 
cells in a growing tumor.
Anaerobic glycolysis allows cells to maintain cellular ATP 
levels under oxygen-deprived conditions at the expense 
of acidosis and lactate accumulation. Virtually all steps of 
glycolysis, from glucose uptake (glucose transporter-1) to 
lactate production (lactate dehydrogenase), are controlled 
by HIF130. Even the limitation of intracellular proton accu-
mulation by CA IX-mediated acidification of the extracel-
lular milieu is a HIF-dependent process that is especially 
pronounced in tumors131. As evident by the Warburg effect, 
these metabolic alterations are specific and stable features 
of tumor cells and thus represent prime targets for a general 
cancer therapy (see below).
Protein synthesis is a major energy-consuming process 
and hence a prime metabolic target to save energy under 
hypoxic conditions (see above). Indeed, general translation 
is down-regulated in hypoxic cells with the exception of the 
HIF signaling pathway, which remains operable even when 
translation of most other transcripts is down-regulated132.
Mitochondrial respiration is controlled in a complex 
manner. HIF-1 reciprocally controls the exchange of cyto-
chrome c oxidase (COX) subunits by inducing the high oxy-
gen-affinity subunit COX4-2 and simultaneously degrading 
the low oxygen-affinity COX4-1 subunit via induction of the 
mitochondrial LON protease133. However, apart from this 
improved oxygen affinity, mitochondrial function can also 
be inhibited, probably when hypoxia becomes more severe, 
by limiting mitochondrial fueling or even by reducing mito-
chondrial mass. Impaired mitochondrial function is likely to 
re-direct non-consumed oxygen to cytosolic enzymes such 
as the PHD oxygen sensors134. Since the PHDs still operate 
under hypoxic conditions135, albeit at a lower rate, oxygen 
re-direction might limit the induction of HIF, establishing a 
negative feedback loop that limits respiratory and metabolic 
changes in a tumor cell.
Paradoxically, also mitochondrial inhibition is HIF-
dependent. HIF induces the gene encoding pyruvate 
dehydrogenase kinase 1, thereby inhibiting pyruvate 
dehydrogenase and converting less pyruvate to acetyl-
coenzyme A (acetyl-CoA), the fuel of the mitochondrial tri-
carboxylic acid (TCA) cycle. This TCA block was sufficient to 
actively suppress respiration, redirect both oxygen and glu-
cose utilization toward cytosolic sinks, and rescue cells from 
hypoxia-induced apoptosis136,137. HIF was further reported 
to inhibit mitochondrial biogenesis and to eliminate mito-
chondria by autophagy, thereby definitively stopping oxy-
gen-based production of ATP138,139. Interestingly, autophagy 
can also be induced by ATF-4, another hypoxia-inducible 
transcription factor up-regulated by preferential translation 
as well as by the PHD oxygen-sensing pathway140,141. Future 
work will help to elucidate the role of this novel branch of 
the hypoxic signaling pathway in energy conservation under 
hypoxic conditions.
4.8. Proliferation and regulation of cell cycle transit
Proliferation of cancer cells under hypoxic conditions 
depends on the cell phenotype, i.e. which cell-cycle-
regulatory genes are functional, as well as on the degree of 
hypoxia.
Generally, cells in S-phase immediately halt DNA syn-
thesis when rendered extremely hypoxic142,143, while cells 
in G
1
 are either arrested at the retinoblastoma protein 
(pRb) checkpoint or proceed to late G
1
 before they become 
arrested at the so-called oxygen-dependent checkpoint in 
late G
1
143,144. Thus, there are, in reality, two different oxygen-
dependent restriction points in G
1
, i.e. the pRB checkpoint 
in early or mid-G
1
, and another checkpoint in late G
1
. The 
molecular mechanisms regulating these two checkpoints 
are not clear. The pRb checkpoint can easily be stated to 
be a result of continued pRb activation under extremely 
hypoxic conditions, but it is not clear why low oxygen ten-
sions have this effect on pRb. The molecular mechanism 
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controlling the O
2
-dependent checkpoint in late G
1
 involves 
the cyclin-dependent kinase (cdk) inhibitor p27Kip1 145–148. It 
has been shown that p27 regulates cell-cycle re-entry after 
hypoxia149. This checkpoint is particularly interesting from 
a cancer therapeutic viewpoint since it has been shown to 
be independent of both p53 and pRb and to operate in both 
normal and malignant cells143,150. Thus, the oxygen-depend-
ent checkpoint in late G
1
 is functional in all cell types so far 
studied. This is a finding which may have cancer-therapeutic 
relevance since mammalian cells seem to be particularly 
prone to become lethally damaged by hypoxia while in 
S-phase151,152. In comparison, cells in G
1
 and G
2
 are far more 
resistant148,153. In fact, most cells rendered hypoxic while in 
G
2
 divide in spite of the lack of oxygen and become arrested 
in the subsequent G
1
.
Hypoxia-induced cell-cycle arrest in S phase has been 
shown to be a consequence of at least two levels of con-
trol. First, both DNA replication and DNA transcription are 
inhibited due to specific inhibition of oxygen-dependent 
enzymes and inhibition of replicon initiation154–156. Second, 
the cell cycle checkpoint machinery is activated in all cell-
cycle phases involving dephosphorylation of pRb and degra-
dation of cyclins143,144,146,157,158. Exposure to moderate hypoxia 
(1300 ppm O
2
) resulted in arrest in S-phase for some cells 
containing active pRb, while cells not containing pRb were 
able to undergo some S-phase progression159.
A protein having a direct cell-cycle-regulatory effect which 
is found to be affected by low oxygen levels (i.e. below about 
1000 ppm) is ribonucleotide reductase. Ribonucleotide 
reductase (RNR) is the enzyme responsible for conversion 
of the four standard ribonucleotides to their deoxyribonu-
cleotide counterparts, and thereby provides the precursors 
needed for both synthesis and repair of DNA160,161. The reduc-
tion of ribonucleotides is the rate-limiting step of DNA syn-
thesis, which makes RNR an important target for cell growth 
control, and several RNR inhibitors are being used, or have 
been proposed, as drugs for chemotherapeutic treatment 
of cancer and a range of infections, such as malaria and 
acquired immunodeficiency syndrome (AIDS)162–164.
4.9. Conserved energy saving responses in hypoxia 
tolerant animal and cancer cells
One major outcome of existing selection pressures under low 
oxygen that is common between lower species and human 
tumors is the gain of hypoxia tolerance. Normally, tumor 
angiogenesis, glycolysis, and apoptotic evasion are regarded 
as the main adaptations that aid the tumor in acquiring toler-
ance75. Compared to these responses, metabolic depression 
as a physiological means to establish hypoxia tolerance, and 
HIF’s role in controlling it, is poorly understood with respect 
to neoplastic cells.
When focusing on invertebrates and some ectothermic 
vertebrates, the metabolic reprogramming that allows main-
taining cellular energetics in homeostasis, albeit at a much 
depressed level, is well characterized as the ultimate hypoxia, 
ischemia, or hypothermia survival response165. However, a 
physiologically and metabolically based hypoxia tolerance 
also occurs in similar form in cells from the deeply hypoxic 
cores of solid human tumors. Regardless of cell transforma-
tion and phylogeny, this form of hypoxia tolerance always 
rests on energy conservation as a long-term survival strategy. 
Many lower animals, for example, acquire their remarkable 
stress resistance through the controlled, yet fully revers-
ible, metabolic rate suppression down to a newly balanced 
ATP supply = ATP demand steady-state termed hypome-
tabolism166. Sustained throughout the entire stress, hypome-
tabolism prevents lethal falls in cellular ATP levels and is 
the single most protective and unifying feature of hypoxia 
tolerant tissues167–169. During this physiological dormancy, 
O
2
 consumption rates equally drop to a small increment of 
normoxic uptake and become dependent on ambient pO
2
 
(oxy-conformance). To match the synchronously declin-
ing ATP production in O
2
-depleted cells, hypometabolism 
requires the immediate and coordinated down-regulation of 
every major ATP-utilizing function in the cell170, including: 
(1) macromolecular, notably protein and DNA synthesis171; 
(2) protein degradation172; (3) ion-motive ATPases, notably 
Na+/K+-ATPase173; and (4) gluconeogenesis170. The further 
these activities can be suppressed, the better and longer the 
cells and organism can withstand deprivations of oxygen165. 
In shifting remaining energy resources toward truly vital 
functions, a largely inhibited protein synthesis (translational 
arrest) and degradation allows, as tolerance hallmark, elec-
trochemical gradients across membranes at reduced perme-
abilities to be maintained (channel arrest)173,174. As a further 
advantage of hypometabolic states, glycolytic fluxes only 
need to be elevated and provide for ATP as much as the resid-
ual energy expenditures require (i.e. weak to absent Pasteur 
effect175,176), explaining why this defense spares fermentable 
fuel, reduces metabolic waste, and extends survival time. 
Along with hypometabolism, cells also enter a non-repli-
cative/non-proliferative “silent S-state” of quiescence177,178. 
Together, hypometabolism, defined as pO
2
-conforming oxy-
gen uptake rates, disengaged protein and DNA synthesis, and 
a non-cycling, quiescent phenotype, underlies the enormous 
resistance in lower organisms in response to a large variety 
of stresses, including hypoxia, ischemia, dehydration, and 
for mammalian hibernators, hypothermia. In all these cases 
and in hypoxic cancer cells75,77, protective mechanisms act 
through critical checkpoints (e.g. translational arrest: via 
transcriptional or post-translational inhibition of initiation 
factors eIF2 and eIF4E, and elongation factor eEF2).
For the tumor, the degree of hypoxia tolerance may be an 
important determinant of the level of hypoxia that can be 
sustained within the mass. Thus, hypoxia tolerance can be 
viewed as a pro-tumor property that provides a molecular 
resistance toward effective therapy. Similar to animal mod-
els, hypometabolic defenses of severely hypoxic (0–0.5% 
O
2
) cancer cells include the (1) partly HIF-mediated sup-
pression of respiration and switch into an oxy-conforming 
uptake mode179,180 that is known, in and of itself, to mediate 
enhanced hypoxia survival to multiple cancer cell lines; 
(2) general silencing of all ATP-costly macromolecular syn-
theses, including the rapid inhibition of replicon initiation 
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in early S-phase of the cell cycle (replicon arrest153,181,182) and 
the marked reduction in the overall rate of protein synthesis 
(translational arrest183–185); and (3) the growth-stalling block 
of cell cycle proliferation, often occurring independent of 
p53 function150 at the G
1
/S phase transition77,186. This ultimate 
defense, cellular quiescence, was first reported from the inte-
rior regions of multiple spheroid models, where “silent-S” 
cells with greatly depressed O
2
 consumption rates increas-
ingly emerged as a function of spheroid growth180,187. It was 
later noted that the development of cellular quiescence, and 
beyond that, of cell death, is not simply a consequence of a 
lack of energy. In fact, many of the spheroid and tumor mod-
els employed saw the emergence of quiescent or necrotic 
cells despite maintaining a normal steady-state level of high 
energy phosphates188–190. This disconnect between energet-
ics and activity or survival strongly suggests that hypoxic/
ischemic cells in the peri-necrotic regions of a spheroid or 
tumor mimic lower organisms by coordinating declining 
ATP production with suppressed energy demands, which 
maintains elevated steady states of high energy phosphates. 
To date, various tumor xenografts have been reported to 
comprise up to 25% silent-S cells191. Since their suppressed 
metabolism is sustained on minimal O
2
 deliveries, quiescent 
cells in the tumor center are refractory to anti-angiogenic 
treatments. Their occurrence also correlates with extreme 
resistance to radiotherapy192,193.
We believe, therefore, that the players and pathways 
(including HIF) behind this physiological hypoxia tolerance 
carry a vast potential for improved therapeutic interventions. 
By targeting these hypoxia tolerance mechanisms, more 
selective diagnostic markers and anti-cancer therapies can 
be anticipated, since almost all healthy tissues in the human 
body are homeostatic in their oxygenation and, arguably, do 
not, or less so, recruit hypometabolic defenses when deoxy-
genated. Together with EUROXY partners Brad Wouters 
(Wp 10B) and Philippe Lambin (Wp 10A), we recently pro-
vided proof-of-principle for the validity of a fly-to-cancer 
translational approach to understand and interfere with 
hypometabolic functions. Our own genome-wide survey 
of the hypoxia transcriptome in hypoxia tolerant cells from 
Drosophila embryos, a state able to survive several days in 
a N
2
 atmosphere, recorded Thor as one of the most strongly 
hypoxia-induced fly genes (~15 times elevated mRNA levels 
at 0.2% O
2
). Thor is Drosophila’s single copy homolog of the 
mammalian translation repressors 4E-binding proteins 1–3 
(4E-BP1–3). When active, 4E-BP’s act by sequestering the 
rate-limiting, cap-binding protein eIF4E from the key trans-
lation initiation complex, eIF4F. Thus, induction of Thor in 
hypoxic fly cells might contribute to inhibiting this branch 
of the ATP-costly protein synthesis. Indeed, fly genetics 
(collaboration: Prof. Pablo Wappner; Leloir Inst., Buenos 
Aires) was used to show: (1) the pronounced induction of 
Thor mRNA in hypoxic flies; (2) the strict requirement of 
HIF for in vivo Thor expression, and (3) the requirement of 
Thor function for Drosophila to adapt to, and recover from, 
hypoxia. Observation “2” implicates HIF for the first time in 
the control of a candidate hypoxia tolerance factor, and thus, 
in the down-regulation of ATP-costly activities in hypoxia. 
Next, we assessed the RNAi-based loss-of-function of 
4E-BP1 for the hypoxic survival and treatment resistance of 
human cancer cells and tumor models (Wouters/Lambin/
Gorr collaboration). Stable expression of a short hairpin 
interfering RNA (shRNA) specific for 4E-BP1 in two human 
cancer cells (HeLa, U87) significantly reduced the viability 
of both lines to prolonged (48 h) and severe (< 0.02% O
2
) 
hypoxia exposure. Moreover, a single dose irradiation (10 Gy) 
of U87 tumor xenografts, made from 4E-BP1 knock-down 
(kd) cells versus empty-vector (ev) transfected control cells, 
revealed a differential radiosensitivity. The post-radiation 
specific growth delay, a measure thought to closely reflect 
the relative number of cells killed by treatment, was always 
significantly higher in the kd tumors compared to ev con-
trol tumors, regardless of tumor end volume194. These data 
strongly suggested a reduction in the viable fraction of radi-
oresistant hypoxic cells in the kd tumors. A reduced toler-
ance to a limiting supply of oxygen in the 4E-BP1 kd tumors 
was indeed evident by increased levels of cleaved Caspase-3 
despite similar extent or severity of intratumoral hypoxia in 
both tumor types (pimonidazole IHC staining). Thus, 4E-BP1 
loss-of-function increases radiosensitivity by decreasing the 
hypoxia tolerance of tumor xenografts, without affecting the 
hypoxic fractions of the xenografts. Diminished hypoxia via-
bility in cells of 4E-BP1 kd tumors was, however, associated 
with a three-fold drop in steady-state ATP concentrations194. 
Thus, from fly to cancer cells, regulating the rates of protein 
synthesis via the control of cap-dependent, eIF4F-driven 
translation is required to facilitate energy conservation and 
to gain hypoxia tolerance. For tumors, this tolerance acqui-
sition is associated with radioresistance. The results of this 
EUROXY effort show that targeting translational controls 
represents an effective new way to sensitize cells to hypoxia 
and solid cancers to radiotherapy.
5. Clinical consequences of tumor hypoxia
5.1. Introduction
Hypoxia is a reduction in the normal level of tissue oxygen 
tension and occurs in many disease processes including 
cancer. It results in the death of both cancer cells and normal 
cells if it is severe or prolonged, but cancer cells can adapt 
to this hostile environment by undergoing genetic changes 
that allow them to survive and even proliferate. It is in part 
this ability to adapt to a hostile environment that predicts the 
malignant potential and aggressive phenotype of a tumor195.
Hypoxia can be broadly categorized into two types: acute 
and chronic. “Acute” or “transient” hypoxia occurs due to 
aberrant blood vessels shutting down and then reopening, 
thus reperfusing hypoxic tissue with oxygenated blood lead-
ing to an increase in free radical concentrations and tissue 
damage. “Chronic” or “diffusion-limited” hypoxia results 
from tumor angiogenesis lagging behind tumor growth. 
The perinecrotic regions of a tumor are located at a median 
distance of 130 µm from blood vessels, reflecting the limit in 
oxygen diffusion196.
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HIF signaling is a key mediator of response to hypoxia 
and regulates the transcription of several genes involved 
in biological processes such as angiogenesis, cell prolifera-
tion and survival, glucose metabolism, pH regulation, and 
apoptosis195,197. Erythropoietin was the first gene discov-
ered to be under HIF regulation198. Besides erythropoietin, 
another well-characterized HIF-regulated gene is VEGF, 
which is involved in regulating endothelial cell prolifera-
tion and blood vessel formation in both normal cells and 
cancer cells. Hypoxia also promotes the undifferentiated 
cell state in stem cells through interaction with the Notch 
signaling pathway. The Notch intracellular domain interacts 
with HIF-1, leading to recruitment of HIF-1 to Notch-
responsive promoters and activation of Notch downstream 
genes199. HIF-1 and VEGF, which is a direct transcriptional 
target of HIF-1, have also been shown to up-regulate Delta 4, 
a ligand for the Notch receptor, important for physiological 
and pathological angiogenesis200. Many of the known onco-
genic signaling pathways overlap with hypoxia-induced 
pathways, and a recent review placed HIF at the center of the 
major oncogene and tumor-suppressor gene pathways201.
5.2. Tumor progression
Genetic instability is induced in hypoxia by several mecha-
nisms (reviewed in reference 202). Hypoxic cells defective in 
p53 and apoptosis have a greater propensity to acquire gen-
omic instability during tumor progression203. Conversely, 
p53 mutated cells with diminished apoptotic potential are 
selected by tumor hypoxia204. Additionally, several genes 
involved in metastasis are induced such as lysyl oxidase205, 
metalloproteases, and urokinase206.
Many other pathways play a role, such as activation of 
mTOR, autophagy, and many different angiogenic factors 
(reviewed in reference 207).
These processes culminate in the observation that when 
genes regulated by hypoxia are up-regulated in cancers they 
are associated with a poor prognosis, independent of treat-
ment modality, but also associated with resistance to each 
modality. Examples include urological cancers, head and 
neck cancer, lung cancer, colorectal cancer208–212, and breast 
cancer, but all common cancers have been investigated and 
this found to be the case in most studies.
5.3. Tumor resistance to conventional drug therapies
The majority of anti-cancer chemotherapy drugs interact 
with DNA directly or indirectly, e.g. cross-linking with cis-
platin and induction of double-strand breaks (DSBs) with 
topoisomerase 2 inhibitors such as epirubicin and etopo-
side. There is a very extensive literature on the ability of 
hypoxia to induce drug resistance, particularly to anthracy-
clines such as epirubicin, but also to other drugs including 
platinum. The mechanisms have not been well defined apart 
from anthracyclines where an acidic extracellular pH blocks 
uptake into the cells. This is certainly one of the major expla-
nations, but Unruh et al.213 showed in transformed mouse 
embryonic fibroblasts deficient in HIF-1 that there was a 
greater sensitivity to carboplatin, etoposide, and radiation. 
This was independent of p53, and in vivo experiments con-
firmed the in vitro results. Agents that did not cause DNA 
DSBs, such as DNA synthesis inhibitors, had equal effects 
on HIF-1 positive and HIF-1 negative cells. There was 
decreased repair of a fragmented reporter gene in normoxic 
HIF-1 deficient cells, suggesting that basal HIF-1 expres-
sion is required for DSB repair gene expression, although 
the detailed mechanism was not understood in these mouse 
embryonic fibroblasts.
More recently, silencing HIF-1 expression by RNAi in 
human non-small cell lung cancer cell lines was reported to 
decrease resistance to cisplatin and doxorubicin by modest 
degrees of hypoxia of 0.5% O
2
214. This confirms the previous 
study, although, again, the mechanism was not described. 
It is important to also evaluate the P-glycoprotein in these 
studies of doxorubicin, because P-glycoprotein is known 
to be a HIF target and affects transport of drugs such as 
epirubicin and doxorubicin. Hypoxia also induced resist-
ance to etoposide, which was multifactorial215. This area of 
research needs more intensive investigation with detailed 
biochemical pathways linked to drug resistance and sensi-
tivity studies.
5.4. Tumor resistance to irradiation
Hypoxia is one of the major mechanisms causing radioresist-
ance, and it is mainly due to lack of O
2
 radicals generated by 
radiation to create DNA damage. However, there are many 
physiological processes regulated by HIF that could also 
contribute to radiation resistance. Moeller et al.216,217 have 
partly elucidated the complex role of radiation interaction 
with HIF. They showed that with conventional doses of radi-
ation used therapeutically, HIF-1 was induced within 24 h in 
tumors of animal models, along with VEGF induction. One 
explanation is that oxygenated cells were killed by radiation 
therapy, and this allowed vessels to expand and reoxygenate 
the hypoxic areas. Although this would have been expected 
to switch off HIF, in fact free radicals produced by this path-
way induced HIF. The source of the free radicals is not yet 
clear but may well be inflammatory cells or macrophages 
induced by the inflammatory response to radiation. The 
effects of HIF induction were complex in that HIF induction 
induced angiogenic factors that helped endothelial cells 
survive radiation damage, and therefore HIF appeared to 
cause radiation resistance from the point of view of allowing 
survival of the vasculature.
On the other hand, HIF-1 produces cell-cycle blockade 
by modifying p21 or p27 expression. In addition, it may inter-
act with p53, so in the few tumor types that have wild-type 
p53, apoptosis may be enhanced, and this was shown also in 
appropriate p53 plus or minus control cell lines. Thus, from 
the tumor cell point of view, HIF-1 expression may enhance 
cell death through p53-dependent pathways and cell cycle 
regulation but enhance survival of vasculature, and the final 
effect will be complex depending on individual genetic fac-
tors in the tumor and in the interaction with the endothelial 
cells. Those studies also showed that HIF-1 on balance 
radiosensitizes tumors by keeping them proliferating when 
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glucose levels are low because of the HIF effect on promot-
ing glycolysis and maintaining ATP levels. Harada et al. also 
found HIF-mediated radioresistance in vivo218.
However, using another model cell line of the mouse 
hepatoma HEPA1 with a HIF-deficient mutation (in ARNT), 
it was found that in vivo HIF-1 defective tumors were more 
readily responsive than the parental ones. The mutant cells 
induced less angiogenesis, but they did not have any differ-
ence in oxygenation status, and in this case radiosensitizers 
did not further sensitize these radioresponsive xenografts219. 
In contrast, HIF-1 proficient xenografts were sensitized by 
misonidazole. In this model, the lack of HIF was associated 
with radiosensitivity, but this did not appear to be due to O
2
 
or vascular effects.
Despite being compatible with the previous reports in 
terms of the in vivo effect, this was a cell autonomous effect 
as shown by mixing experiments whereby the overall sensi-
tivity depends on the proportion of HIF-deficient cells, and 
this implies that the mechanism differs and is not due to a 
paracrine vascular effect. Further work needs to be done to 
characterize the vascular response and free radical response 
in this model for comparative purposes.
6. Taking advantage of the hypoxic tumor 
phenotype
6.1. Gene signatures for prognosis and stratification
6.1.1. How to select patients for treatment
The evidence showing that hypoxia is important in tumor 
progression and prognosis has spurred research into devel-
oping therapies that target hypoxic cells. Therapeutic strat-
egies include modification of the hypoxic environment or 
targeting components of the HIF-1 signaling pathway67,76,220. 
There is therefore a need for reliable methods to identify 
hypoxic tumors and those patients most likely to benefit 
from hypoxia-targeted therapy. Currently the level of tumor 
oxygenation is assessed by direct or indirect methods. The 
main direct approach is to measure intratumoral pO
2
 with 
needle electrodes. Indirect techniques include the immu-
nohistochemical analysis of biopsies after injection of 
bioreductive drug markers of hypoxia, immunohistochemi-
cal analysis of expression of hypoxia-regulated proteins, 
imaging techniques, and more recently gene microarray 
analysis.
6.1.2. Oxygen needle electrode
The Eppendorf polarographic needle electrode is the main 
technique of direct pO
2
 measurement. Tissues are defined 
as hypoxic or normoxic based on the median pO
2
 level or 
the “hypoxic fraction” (percentage of pO
2
 values below a 
set level, typically, 2.5, 5, or 10 mmHg, designated HP2.5, 
HP5, and HP10 respectively)221. The “hypoxic subvolume” 
(HSV) is another parameter of tumor oxygenation, defined 
as the hypoxic fraction multiplied by the total tumor vol-
ume, designed to more closely correlate with the absolute 
number of hypoxic cells in the tumor222. However, use of the 
technique is limited by the tumor sites that are accessible 
to the probe (e.g. head and neck squamous cell carcinoma 
(HNSCC) and cervical cancer), dependency on a technically 
skilled user, and failure to differentiate between acute and 
chronic hypoxia.
6.1.3. 2-Nitroimidazole binding agents
Pimonidazole hydrochloride is a 2-nitroimidazole that 
has been used in human clinical trials223,224. When injected 
intravenously, it undergoes enzymatic reduction and bind-
ing to macromolecules at low cellular oxygen tensions. 
Antibodies raised against the bound products are used to 
visualize hypoxia. Cells binding to pimonidazole are inter-
preted as existing at pO
2
 values <10 mmHg225. Pimonidazole 
binding assays provide hypoxia measurements with a 
high degree of spatial resolution. However, in a study of 
cervical cancer, there was no correlation between pimo-
nidazole binding and oxygen electrode measurements of 
hypoxia226. Pimonidazole binding has been shown to relate 
to increased rates of early locoregional recurrence after 
radiation treatment224.
6.1.4. Tumor immunohistochemistry
Immunohistochemical detection of HIF-1 demonstrates 
patterns of expression similar to that of CA IX, with typical 
peri-necrotic staining, consistent with the distribution of 
diffusion-limited hypoxia227–229. The relationship between 
tumor HIF-1 expression and patient outcome has been 
discussed earlier. The difficulty in using tumor HIF-1 
expression as an intrinsic marker of hypoxia is that its acti-
vation can occur in the presence of oxygen, for example in 
renal cell carcinoma (RCC) due to the loss of von Hippel–
Lindau  protein (pVHL)230. Since other proteins, such as CA 
IX, can also be regulated by oxygen-independent pathways, 
it is imperative that these markers are assessed in the light 
of comparative studies with specific hypoxia markers.
CA IX is a zinc metalloenzyme that catalyzes the reversible 
hydration of carbon dioxide to bicarbonate and hydrogen 
ions and is involved in acid–base balance. The intratumoral 
expression of CA IX has been characterized in a variety of 
tumors, and high CA IX expression was associated with 
decreased survival in HNSCC, lung, cervix, and breast 
cancer231–235. Koukourakis et al. showed that HNSCCs with 
high CA IX expression had a poorer complete response rate 
to chemoradiotherapy, whilst Loncaster et al. demonstrated 
that CA IX expression was an independent prognostic fac-
tor for disease-specific and metastasis-free survival but 
not related to local control after radiotherapy in cervical 
cancer231–234.
Several studies have examined the correlation between 
the different techniques. In cervical cancer, there was a 
significant positive correlation between the level of tumor 
hypoxia (HP5) and the extent of CA IX expression234. In 
another study of cervical cancer, there was a weak negative 
correlation between HIF-1 expression and median pO
2
 but 
no relationship with HP5236. However, Mayer et al. showed 
no correlation between tumor oxygenation and CA IX or 
HIF-1 expression in tissue samples originating from oxygen 
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electrode tracks of locally advanced cervical cancers237,238. In 
cervical cancer, CA IX showed a substantial but incomplete 
overlap with pimonidazole in two studies120,239. There was 
weak but significant correlation between pimonidazole and 
CA IX in HNSCC, with CA IX expression observed at shorter 
distances from blood vessels, implying that CA IX up-reg-
ulation occurs at pO
2
 levels higher than those required for 
pimonidazole binding224. In a study of HNSCC, no correla-
tion was shown between HIF-1 and pimonidazole240, whilst 
in cervical cancer, there was a weak correlation between 
HIF-1 and pimonidazole236.
It is also possible that secreted markers of hypoxia could 
be monitored by a blood sample. Osteopontin (SPP1) is 
a marker that is associated with tumor hypoxia, and its 
plasma concentration is easily obtainable241. A recent study 
showed that high plasma concentrations of osteopontin in 
patients with HNSCC are associated with a poor prognosis 
after radiotherapy, and that the prognosis in this group of 
patients can be improved by use of the hypoxia radiosensi-
tizer, nimorazole, with radiotherapy242.
6.1.5. Imaging
Positron emission tomography (PET) allows the in vivo 
measurement and quantification of physiological processes 
using short-lived positron emitting radiopharmaceuticals. 
Most radiopharmaceuticals under development for hypoxia 
detection use 2-nitroimidazole as the targeting moiety and 
a radioactive element, such as 18F, 67Cu, or 64Cu, amenable 
to nuclear medicine imaging. PET and PET/CT (computed 
tomography) offer the possibility of in vivo mapping of 
regional tumor hypoxia as well as monitoring of therapy 
through follow-up mapping of hypoxia. Additionally, PET/
CT has the potential to be a single imaging modality for 
whole body staging. It also allows a more accurate estima-
tion of the hypoxic tumor volume, which is important in 
planning radiation treatment. Numerous PET studies evalu-
ating hypoxia in different tumor types have been conducted 
and were recently reviewed by Krause et al.243.
6.1.6. Gene expression profiling
DNA microarrays are platforms on which several hundred 
or thousand oligonucleotides or cDNA of known genes are 
printed. Microarray technology allows simultaneous visu-
alization of the expression of potentially all the genes within 
a cell population or tissue sample, revealing the “transcrip-
tome.” The analysis of microarray data is commonly called 
“gene expression profiling” (GEP). “Prognostic signatures” 
can be obtained from GEP data, representing a relatively 
small number of genes that can be valuable in directing 
appropriate therapy and predicting outcome244. The ability 
to measure the expression of tens of thousands of genes in 
a single experiment is an enormous increase over the previ-
ously available techniques for measuring gene expression, 
which included northern blot and reverse transcription-
polymerase chain reaction (PCR), where only a few genes 
could be studied at a time; however, these techniques are 
still required to confirm expression of genes after microarray 
analysis. The interpretation of microarray data is further 
complicated by the complexity of the biological systems, 
such as the relationship between mRNA levels and protein 
abundance.
The largest drawback of microarray analysis is the lack 
of well-defined standards for their use, interpretation, and 
validation245. In an attempt to standardize the presentation 
and annotations associated with microarray experiments, 
the Minimum Information about Microarray Experiments 
(MIAME) criteria have been established in order that suf-
ficient information is recorded about each experiment 
to interpret the results, enable comparisons, and permit 
replication246.
GEP can distinguish between normal, premalignant, and 
malignant epithelium and may be able to characterize more 
accurately the malignant or premalignant status of surgical 
resection margins247. Evidence for the extent of its use as a 
prognostic biomarker for response to therapy and survival is 
limited at present.
Hypoxia regulates a complex gene profile, and how the 
pattern of expression and extent of up-regulation of path-
ways relates to response to therapy and outcome is poorly 
understood. Defining gene profiles regulated by hypoxia 
and relating them to the above outcomes may provide a 
functional classification of tumors relevant to selection for 
specific therapies, e.g. bioreductive drugs, anti-angiogenic 
drugs, carbonic anhydrase and HIF inhibitors, and radiation. 
It is limited, however, by their variability of expression within 
a tumor, the lack of hypoxia specificity of individual proteins, 
and the complex inter-relationships between molecular 
pathways in different types of tumors. Establishing tumor 
type-specific or -independent hypoxia gene signatures 
would be a major advance in this area of research.
Therefore, we assessed the mRNA profile of HNSCC 
samples and defined an in vivo hypoxia metagene by clus-
tering around the RNA expression of a set of known hypoxia-
regulated genes. The validity of the method was confirmed 
by showing that the metagene contained many previously 
described in vitro derived hypoxia response genes and was 
prognostic for treatment outcome in independent datasets 
of many tumor types.
Affymetrix U133plus2 GeneChips were used to profile 59 
head and neck squamous cell cancers. A hypoxia metagene 
was obtained by analysis of genes whose in vivo expression 
clustered with the expression of 10 well-known hypoxia-
regulated genes (e.g. CA IX, GLUT1, VEGF). To minimize 
random aggregation, strongly correlated up-regulated genes 
appearing in more than 50% of clusters defined a signature 
comprising 99 genes, of which 27% were previously known 
to be hypoxia associated (Figure 5). The median RNA expres-
sion of the 99 genes in the signature was an independent 
prognostic factor for recurrence-free survival in a publicly 
available head and neck cancer dataset, outperforming the 
original intrinsic classifier. In a published breast cancer 
series, the hypoxia signature was a significant prognostic 
factor for overall survival independent of clinicopathologic 
risk factors and a trained profile.
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The up-regulated gene list HS-up (Table 1) contained 
a number of genes previously described as induced by 
hypoxia, including those involved in glucose metabolism 
(e.g. aldolase A fructose-bisphosphonate, glyceraldehyde-
3-phosphate dehydrogenase), angiogenesis (ANGPTL4, 
placental growth factor), cell migration (trophoblast 
 glycoprotein), and the regulation of apoptosis (BNIP3). 
The known genes represent a broad spectrum of molecular 
pathways involved in cellular response to hypoxia. Some 
of the genes have also been described in RNA profiles of 
HNSCC, e.g. interleukin-8245 and plasminogen activator 
urokinase. Genes not previously reported to be up-regulated 
under hypoxia include MTX1, BCAR1, HES2, PSMA7, and 
SLCO1B3.
Hypoxia metagene as a prognostic factor in an inde-
pendent HNSCC dataset As no treatment outcome data 
were available for our HNSCC dataset due to a short 
follow-up, it was not possible to train our hypoxia meta-
gene on outcome or test its significance on the present 
dataset. Therefore, to explore whether our signature 
could provide prognostic information, it was applied to 
a publicly available dataset248. The characteristics of our 
59 metagene-generating and the 60 literature HNSCCs 
were compared using 2. Patients in the Chung dataset 
were stratified according to HS-up quartiles or two groups 
(upper quartile vs. rest). High HS-up expression was an 
independent adverse prognostic factor for recurrence-
free survival (Figure 6); the hazard ratio (HR) for the upper 
quartile vs. the rest was 3.64 (95% confidence interval (CI) 
1.43–9.31).
Hypoxia metagene as a prognostic factor in another 
cancer type The ability of HS-up to predict outcome was 
investigated in a breast cancer series. Increasing HS-up 
was a significant adverse prognostic factor for metastasis-
free (Figure 7A and B) and overall survival when patients 
were stratified by either quartiles or two groups. The HRs 
for metastasis-free survival were 1.62 (95% CI 1.33−1.98) 
for quartiles and 2.83 (95% CI 0.78−3.38) for two groups. 
In a multivariate analysis including HS-up with the clini-
cal variables included in the original study, HS-up retained 
significance for metastasis-free (p = 0.003; Figure 7B) and 
overall (p = 0.002) survival. In a multivariate analysis includ-
ing the 70-gene trained intrinsic signature, HS-up retained 
significance for overall survival (p = 0.003). When a cell line-
derived wound-response signature was included, HS-up 
retained independent prognostic significance for metasta-
sis-free (HR = 2.80; 95% CI 0.09−7.22; p = 0.033) and overall 
(HR = 3.01; 95% CI 1.06−8.58; p = 0.038) survival.
The work highlights the validity and potential of using 
data from analysis of in vitro stress pathways for deriving 
Figure 5. Gene array heatmap for hypoxia-regulated genes in head and 
neck ranked by degree of CA IX expression from left to right. The further 
to the right a tumor is, the greater is the degree of coordinated up-regula-
tion of the profile. Note that every patient is different and no one marker 
is expressed in all hypoxic cases.
Table 1. Gene list for hypoxia-clustered genes.
MTX1 P4HA1 GAPD PSMA7
ADORA2B PFKFB4 GMFB PSMB7
AK3 PGAM1 GSS PSMD2
ALDOA PVR HES2 PTGFRN
ANGPTL4 SLC16A1 HLG2 PYGL
C20orf20 SLC2A1 IL8 RAN
MRPS17 TEAD4 KCTD11 RNF24
PGF TPBG KRT17 RNPS1
PGK1 TPI1 Kua RUVBL2
AFARP1 TUBB2 LOC149464 S100A10
ANLN VEGF LOC56901 S100A3
B4GALT2 VEZT Lrp2bp SIP1
BCAR1 AD003 MGC14560 SLC6A10
BMS1L ANKRD9 MGC17624 SLC6A8
BNIP3 C14orf156 MGC2408 SLCO1B3
HOMER1 C15orf25 MIF SMILE
HSPC163 CA12 MRPL14 SNX24
IMP-2 CA9 NUDT15 SPTB
KIAA1393 CDCA4 PA/VR TFAP2C
LDHA COL4A5 PDZK11 TIMM23
LDLR CORO1C PLAU TMEM30B
MGC2654 CTEN PLEKHG3 TPD52L2
MNAT1 DKFZP564D166 PP ARD VAPB
NDRG1 DPM2 PP P2CZ XPO5
NME1 EIF2S1 PP P4R1  
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a biological metagene/gene signature in vivo. This also 
delivers a hypoxia gene profile for further clinical use and 
development.
Future plans Several key issues are as follows:
development of a reduced signature•	
comparison of metagenes between different cancer •	
types
development of a common hypoxia metagene for all •	
cancer types
These are currently being performed, and early results 
indicate that a common metagene of 34 genes can be 
derived. We have compared our results with our published 
metagenes for hypoxia250–252 and found superior perform-
ance in classifying outcome.
integration of other hypoxia markers, hypoxia-induced •	
miRNA.
We recently showed that a hypoxia-induced miRNA, 
 miR-210253, provided strong independent prediction of poor 
outcome in breast cancer, and was correlated with the hypoxia 
metagene. However, since its targets are not regulated at the 
transcriptional level, this is likely to provide additional infor-
mation to the metagene. We are currently analyzing this and 
also assessing other hypoxia-inducible miRNAs.
Validation of a reduced signature in randomized trials In 
a collaboration with Prof. Catharine West of Manchester 
University, a reduced common metagene plus miR-210 will 
be analyzed in RNA extracted from paraffin blocks from the 
following randomized trials:
•	 Nimorazole trial in head and neck (H&N) can-
cer (n = 200). The Danish DAHANCA 5 trial was a 
randomized double-blind phase III study of nimorazole 
as a hypoxic radiosensitizer of primary radiotherapy in 
supraglottic larynx and pharynx carcinoma.
•	 BCON trial in bladder cancer (n = 150). The BCON trial 
was designed to test whether hypoxia-modifying carbo-
gen and nicotinamide with radiotherapy could improve 
local control compared with radiotherapy alone—based 
on results from a successful phase II trial. The phase III 
trial completed accrual in April 2006 with a final accrual 
of 333 patients.
•	 ARCON trial in H&N cancer (n = 100). The ARCON 
phase II trial enrolled 215 patients with H&N cancer. 
Patients received accelerated radiotherapy with car-
bogen breathing and nicotinamide. The trial showed 
that ARCON yielded high locoregional control rates in 
advanced H&N cancer.
This will allow us to show whether the hypoxia meta-
gene defines a subgroup that derives the most benefit from 
hypoxic modulation, and will provide the basis to be able 
to use this in prospective randomized trials and patient 
management.
Figure 6. Cox multivariate analysis-derived hazard ratios (HRs) with 95% 
confidence intervals (CIs). Variables used in the original publication of 
an independent HNSCC patient dataset were entered in the model along 
with HS-up. HS-up was entered as a continuous variable (fractional 
rank varying from 0 to 1), and the HR reported represents the risk for an 
increasing HS-up quartile (the HR for the two ends of the spectrum was 
14.83; 95% CI 1.80−122.35).
Figure 7. Kaplan–Meier plots of metastasis-free survival in 295 patients 
with breast cancer. The data were taken from reference 249. (A) Stratified 
according to HS-up quartiles. The numbers of events and patients for 
increasing quartiles were 12/73, 18/73, 20/74, and 38/73. (B) Stratified by 
highest HS-up quartile (0.75−1) vs. the remaining three quartiles (0−0.75). 
The numbers of events and patients for the two arms were 50/220 and 
38/73, respectively.
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6.2. Renal carcionmas and HIF-1/HIF-2
Kidney cancer is relatively common, tends to present late, 
and remains an important cause of morbidity and mortal-
ity. Illustrating this, the American Cancer Society estimated 
that there were more than 35,700 new cases of kidney cancer 
and 12,480 deaths from kidney cancer in the United States in 
2004. Kidney cancer is categorized on histological grounds, 
and the commonest form is clear cell renal cell carcinoma 
(CCRCC). The majority of CCRCC (~70%) shows biallelic 
inactivation of the von Hippel–Lindau (VHL) tumor sup-
pressor gene, resulting in constitutive activation of HIF. VHL 
defective CCRCC cell lines grown under standard conditions 
show high-level expression of the HIF-driven gene program, 
including GLUT1, VEGF, and CA IX. Complementation with 
VHL restores regulation of the HIF pathway by oxygen, and 
also suppresses tumor growth in xenograft assays. About 
1 in 30,000 individuals carries a germline mutation in the 
VHL gene, resulting in the inherited tumor syndrome von 
Hippel–Lindau disease. This includes a ~70% lifetime risk of 
CCRCC, and tumors involve a somatic second hit leading to 
biallelic inactivation of VHL.
Understanding how VHL acts as a tumor suppressor gene 
in renal epithelium should provide an important insight both 
into kidney cancer, and more generally into the role of the 
HIF pathway in tumor biology. VHL has a number of other 
actions besides its role in the ubiquitin E3 ligase complex 
that captures HIF -subunits. Nevertheless, several lines of 
evidence support the concept that suppression of HIF, and 
particularly HIF-2, is central to VHL’s tumor suppressor 
action in the renal epithelium. A powerful system for exam-
ining the sequence of events leading from VHL inactivation 
to renal cancer is provided by the ability to detect micro-
scopic foci of HIF activation in the kidneys of patients with 
a germline VHL defect using immunohistochemistry for CA 
IX. This shows that “second hits” are very common, and that 
they are not generally associated with increased prolifera-
tion, implying that further events are required for progres-
sion to malignancy254. The earliest lesions detected by this 
method (seen as single cells in paraffin-embedded sections) 
express HIF-1, with more complex lesions and tumors 
expressing both HIF-1 and HIF-2. Very early lesions show 
loss of several epithelial characteristics (e.g. specialized 
junctions, see below), increased vascularization, clear cell 
morphological changes, and expression of the intermediate 
filament vimentin.
Experiments in rodents show that decreasing oxygen 
delivery to the kidney leads to tubular epithelial cells acti-
vating HIF-1 expression, but not HIF-2 expression255. In 
renal carcinoma cells, isoform-specific manipulation of 
HIF-1 and HIF-2 has shown that some changes in gene 
expression associated with CCRCC are driven by a specific 
HIF isoform: BNIP3 and CA IX were increased by HIF-1 
and CCND1 by HIF-2256. Importantly, HIF-2 expression 
down-regulated HIF-1, which may be important in effect-
ing a switch between different types of HIF response. In 
xenograft experiments, expression of HIF-1 in 786-O cells, 
which express only HIF-2, slowed tumor growth.
In an analysis of 42 clinical CCRCC specimens we found 
that 26 showed activation of HIF in all cells, consistent with 
loss of VHL function. In eight of these cases there were areas 
of tumor within which HIF-1 labeling was completely 
absent while expression of HIF-2 was preserved (Tran 
and Maxwell et al., unpublished results). Six of eight of 
these cases presented with metastatic disease or developed 
metastases within 6 months. In contrast, a single case of the 
18 in which HIF-1 was present (6%) developed metastatic 
disease (2, p ≤ 0.001). With the caveat that this is a small 
series, it suggests that tumors with predominant expression 
of HIF-2 and reduced or absent HIF-1 are more likely to 
be associated with metastases.
In some cases a sharp boundary could be identified 
between a portion of the tumor expressing HIF-2 alone 
and adjacent tumor expressing both HIF -subunits This 
allows direct comparison of a subpopulation in the tumor 
which has lost HIF-1. Interestingly these areas had much 
lower CA IX expression, consistent with this being a HIF-1 
target in CCRCC. Ki67 labeling showed a striking increase 
in proliferation index (p < 0.0001) in areas with predominant 
HIF-2 expression. Finally, we examined the key cell regula-
tory protein CCND1, which was expressed at a substantially 
higher level in the area that expressed only HIF-2.
Taken together, these findings suggested that evolution to 
malignancy in VHL-defective cells involves evolution from 
an exclusive HIF-1 program in normal epithelium (which 
predisposes to apoptosis) to an exclusive HIF-2 program 
in advanced tumors, and that selective inhibition of HIF-2 
might be an attractive treatment strategy.
Importantly, several findings show that HIF-2 activation 
in renal epithelium is not sufficient for malignant trans-
formation. First, immunohistochemistry for the adherens 
 junction protein E-cadherin reveals multiple foci of HIF-2 
activation in VHL patients (Tran and Maxwell et al., unpub-
lished results). These are distinct from those expressing 
CA IX; like the HIF-1 lesions identified on CA IX immu-
nohistochemistry they show little evidence of increased 
proliferation. Second, analysis of mice with cell-specific 
biallelic inactivation of VHL in the renal epithelium shows 
that although the majority of cells activate HIF-1, a subset 
activate HIF-2. Third, expression of a transgene encoding 
constitutively active for HIF-2 does not result in striking 
proliferation (Wiesener et al., unpublished results).
The downstream consequences of VHL loss-of-function 
that contribute to the tumor phenotype are extensive and 
incompletely understood. Of particular interest, VHL loss-of-
function results in a marked decrease in formation of adhe-
rens junctions and of tight junctions in premalignant foci in 
VHL patients257,258. VHL re-expression rescues these charac-
teristics in VHL-defective renal cancer cells. The effects on 
tight and adherens junctions are independent of each other 
(demonstrated by forced expression of E-cadherin, occlu-
din, and claudin 1). HIF activation was shown to mediate 
the effects, at least in some cell backgrounds. In addition, 
VHL re-expression in renal carcinoma cells leads to forma-
tion of a primary cilium, which is a characteristic of normal 
D
o
w
n
lo
ad
ed
 B
y:
 [
ET
H-
Bi
bl
io
th
ek
] 
At
: 
10
:3
1 
15
 A
pr
il
 2
00
9
Taking advantage of tumor cell adaptations to hypoxia  23
renal epithelium, and this involves HIF suppression257. This 
aligns VHL disease with the “ciliary hypothesis” which sug-
gests that defects in the primary cilium in a variety of non-
malignant renal cystic conditions lead to cyst development. 
These findings link HIF activation to important aspects of 
cancer biology; decreased cell adhesion, and epithelial-to-
mesenchymal transition. Interestingly, in the CCRCC cell 
lines studied, the effect on cilia and tight junctions appears 
to be more dependent on HIF-1 while adherens junctions 
are more influenced by HIF-2.
Therefore, HIF activation plays a critical role in the major-
ity of CCRCC and is responsible for many of the phenotypic 
characteristics of the tumor compared to normal epithe-
lium. HIF activation has pleiotropic downstream conse-
quences that are in part governed by which HIF -isoform is 
expressed; which of these are most important in the malig-
nant phenotype is not fully understood. The mechanisms 
governing the expression of HIF-1 vs. HIF-2 expression 
in renal epithelium remain to be determined; determining 
the factors that control this in normal cells and the genetic 
and epigenetic alterations that influence it in evolution of 
renal cancer will be important.
6.3. Imaging acute and chronic tumor hypoxia
The most important goal of cancer treatment is to offer 
patients an improved quality of life by achieving a cure 
for the disease, increasing their lifespan, or diminishing 
symptomatic side effects. Up to now the standard treatment 
options have included surgery, chemotherapy, and radio-
therapy (RT). However, the effects of these treatments have 
been hampered by the presence of low oxygen regions het-
erogeneously spread within the tumor. These regions, also 
called hypoxia, are due to the unusual, chaotic, and insuffi-
cient organization of blood vessels within the tumors result-
ing in an inability to deliver oxygen and nutrients259,260 and 
in a three-fold lower amount of lethal DNA lesions occur-
ring upon irradiation261. The importance of hypoxia has 
been demonstrated clinically, where it has been shown that 
patients with a hypoxic tumor have a worse outcome262–265. 
This has led to clinical efforts being made toward overcom-
ing hypoxia, by focusing on eliminating hypoxia either by 
breathing high-oxygen gas mixtures or replacing oxygen 
with radiation-sensitizing drugs220,266.
This unique tumor microenvironment therefore makes 
hypoxia an attractive target for newly developed drugs 
to increase the radiation dose within these areas267. To 
exploit this tumor characteristic, identification of hypoxia 
in tumors is essential. To date, various methods have 
been available to measure tumor oxygenation, includ-
ing oxygen electrodes268,269, antibody-based detection of 
exogenous270,271 or endogenous120,272 hypoxia markers, and 
gene signatures273. However, these methods have been 
limited by practical challenges such as invasiveness and 
tumor accessibility. Furthermore, there is spatial as well 
as temporal heterogeneity, both in distribution of hypoxia 
and the hypoxia response, which results in a necessity for 
non-invasive three-dimensional imaging, which can be 
performed in a repeated fashion. The real power of molecu-
lar imaging goes beyond diagnosis by identifying different 
biologic processes within a tumor using tracers that charac-
terize both genotypic and phenotypic signatures. PET with 
several hypoxia-specific tracers has the ability to quantify 
hypoxia, provides a basis for rational patient selection, and 
guides treatment274,275.
[18F]Fluoromisonidazole ([18F]FMISO) was the first radi-
olabeled 2-nitroimidazole derivative proposed for hypoxia 
imaging with PET276. This tracer has been evaluated exten-
sively for the detection of tumor hypoxia both preclinically, 
using different animal models277,278, and clinically, for dif-
ferent cancer types279,280. Our group was the first to validate 
the potential of this PET technique using a nitroimidazole 
related histopathology assay281, which was confirmed by 
others282. In terms of impact of hypoxia on outcome, pre-
therapy hypoxia values are important, because most biologi-
cal changes occur early, persist throughout therapy, and are 
used to predict survival283. Several studies also investigated 
the post-therapy [18F]FMISO levels and found a decreased 
hypoxia distribution, suggesting that reoxygenation occurred 
as a consequence of radiation284,285. Tumor control prob-
ability models based on repeated [18F]FMISO-PET acquisi-
tions during RT, combining the perfusion efficiency and the 
degree of hypoxia to estimate the reoxygenation time, are 
the key for future hypoxia image-guided dose escalation in 
RT286 and in planning boost RT to persistent hypoxic sub-
volumes267. Although [18F]FMISO provides a validated and 
reliable measurement of tissue hypoxia for individualized 
cancer treatment, it does not cope with different biological 
variables such as increased glycolysis. Therefore, it has been 
suggested to also include [18F]fluorodeoxyglucose (FDG)-
PET in order to assess additional functional information 
during pre- and post-treatment287.
Although [18F]FMISO is extensively validated and used in 
clinical settings as a hypoxia marker, there are some concerns 
about the stability of the fluorin-18 linkage, the formation of 
metabolites in blood and urine, and the limited diffusion 
in tumor tissues288,289. To overcome these problems, second 
generation hypoxia markers (e.g. FETNIM, FETA, EF3, EF5, 
FAZA, ATSM, etc.) have been developed that are more water 
soluble and have demonstrated a lower degradation, which 
results in higher tumor to background contrast, as reviewed 
in references 285, 287, and 290. These new markers have 
been extensively tested in order to replace [18F]FMISO, but 
results have not always been convincing. For example, our 
group has demonstrated that [18F]EF3 uptake in an experi-
mental rat model was slightly faster cleared and showed a 
lower background compared with [18F]FMISO. However, the 
[18F]EF tumor uptake was significantly lower, resulting in not 
being superior over [18F]FMISO288.
On the other hand, [18F]FMISO is probably not the most 
ideal tracer in imaging fluctuating tumor hypoxia, since 
it demonstrates slow clearance kinetics upon (radiation 
induced) reoxygenation once [18F]FMISO is trapped in the 
cells290. Therefore, instead of using bioreductive exogenous 
drugs, our laboratory is investigating the possibility of 
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imaging the endogenous marker carbonic anhydrase (CA) 
IX. CA IX expression is dramatically increased in a variety 
of human tumors, whilst its expression in normal tissues 
is low291. This tumor-associated up-regulation of CA IX is 
the result of a strong transcriptional activation of the CA IX 
gene by HIF-1120. Expression of CA IX in tumors is associ-
ated with poor prognosis, tumor progression, and aggres-
siveness, suggesting that CA IX may be a good therapeutic 
target128. Furthermore, CA IX also seems to be implicated in 
tumorigenesis via its capacity to modulate cell adhesion and 
acidification of the tumor microenvironment125.
Various sulfonamide inhibitors of CA IX (CAI) have been 
developed over recent years293. Several of these inhibitors 
were found to be able to reduce the extracellular acidosis 
caused by hypoxia up-regulated CA IX294 and could pos-
sibly be used as components of therapeutic strategies to 
increase extracellular pH, resulting in decreased tumor 
aggressiveness. Recently, a fluorescent derivative (Figure 8) 
with high affinity for CA IX has been developed295, which 
has been shown to inhibit the hypoxia-mediated tumor 
acidification125,128. The Pastoreková group demonstrated 
that this derivative was able to bind CA IX expressed under 
hypoxic conditions, but not under aerobic conditions, offer-
ing an attractive possibility of imaging CA IX non-invasively 
using sulfonamide-based compounds125.
Based on these reports, our group further investigated 
the binding properties of those sulfonamides (CAI) in dis-
tinguishing cells that have been hypoxic and thus show an 
increase in hypoxia-regulated genes, but then reoxygenated. 
Immunofluorescence analysis demonstrated a significantly 
higher binding of CAI at cells exposed to hypoxia, compared 
with their normoxic counterparts, corresponding with an up-
regulation of CA IX expression (Figure 9A and B). Although 
CA IX expression levels remained high upon reoxygena-
tion, CAI binding was dramatically reduced and no longer 
correlated with CA IX expression128. Furthermore, CAI that 
was bound under hypoxic conditions remained associated 
with cells during reoxygenation. This CAI bound fraction 
was gradually lost with time during reoxygenation, falling 
to near background levels after more than 1 h128, which is 
much faster than the normal turnover of CA IX129. Inhibitor 
binding is furthermore HIF-1 and cell-type independent, 
allowing for the distinction between actual and previously 
hypoxic cells. Recent studies indicate the possibility of using 
iodine-labeled CA IX antibody to monitor CA IX expression 
non-invasively296,297. Our data also demonstrate that anti-
bodies against CA IX cannot discriminate between hypoxic 
and aerobic cells, since antibody binding is also observed 
upon reoxygenation, due to the normal turnover of CA IX129. 
Co-localization between CA IX inhibitor and monoclonal 
antibody was only observed under hypoxic conditions, as 
seen by the yellowish color (Figure 9C)128.
In summary, consequences of heterogeneously spread 
hypoxic areas within solid tumors are well known and spe-
cific treatments are under investigation. Therefore, adequate 
measurements of tumor oxygenation are the key for hypoxia 
image-guided dose escalation in radiotherapy. However, 
a lack of simple and efficient methods slows down the 
understanding of hypoxia. Recently, molecular markers of 
hypoxia such as CA IX have been under investigation, but no 
discrimination can be made between hypoxic and aerobic/
reoxygenated cells based on antibody imaging. Therefore, 
CAI imaging probes are promising alternatives due to their 
ability to discriminate between such areas. Further in vivo 
investigations are ongoing within our institute. Our data 
demonstrate the possibility not only for imaging fluctuat-
ing hypoxia in vivo, but also for increasing radiotherapy 
efficiency, by specific targeting of CA IX, which will result in 
individualized patient treatment.
6.4. Bioreductive drugs
6.4.1. Introduction
The recognition of the importance of hypoxia in tumor 
response to therapy has precipitated a number of thera-
peutic approaches to overcome this resistant population. 
The potential use of bioreductive drugs was first proposed 
in the early 1970s. The concept was forwarded by Alan 
Sartorelli298 who suggested that hypoxia could be exploited 
in cancer therapy by using bioreductive prodrugs that would 
be activated specifically in hypoxic cells to yield cytotoxic 
product(s). As hypoxia is rare in normal tissues, the idea was 
that such agents would have limited normal tissue toxicity 
whilst killing the tumor cell population with a recognized 
refractory phenotype. The classical development pathway 
for bioreductive drugs was guided toward their use in com-
bination with agents that show limited effectiveness against 
hypoxic cells. Radiation remains an obvious choice, where 
the need for oxygen to reveal cytotoxicity is well recognized4,5. 
In addition, many other chemotherapy agents are preferen-
tially more effective in the presence of oxygen7. However, 
with our greater understanding of the cellular response to 
hypoxia, it is becoming increasingly apparent that targeting 
Figure 8. Chemical structure of CA IX-selective sulfonamides: fluores-
cein-thioureido-homosulfanilamide. (Reprinted with permission of 
Elsevier.)
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the hypoxic tumor population will not only overcome poten-
tial treatment resistance to conventional therapy, but will 
also selectively remove an aggressive subpopulation associ-
ated with the development of metastatic disease.
6.4.2. Prototype agents in the development of 
bioreductive drugs
Originally, two classes of bioreductive agents were devel-
oped simultaneously: the quinones and the nitroaromatics. 
The prototype quinone agent was mitomycin C (MMC). In 
clinical use from the 1950s, MMC was only recognized as 
having bioreductive properties three decades later299–301. 
The development of the nitroaromatic class began with the 
hypoxic cell radiosensitizer misonidazole, which was found 
to have equivalent or greater hypoxia-selectivity than MMC. 
For both agents (and all bioreductives developed subse-
quently), bio-activation depends not only on hypoxia but 
also on reductase enzymes present within the cell. Indeed 
the precise enzyme complement can markedly influence 
potency and toxicity. Both MMC and misonidazole can 
undergo one electron reduction to yield cytotoxic products. 
This reaction is readily reversed in the presence of oxygen. 
For MMC the one-electron product is the semi-quinone 
radical anion that causes DNA cross-links as the cytotoxic 
lesion. NADPH/cytochrome p450 reductase (P450R) has 
been implicated as a key bioactivating enzyme yielding 
this product under hypoxic conditions. However, MMC 
can also be reduced in an oxygen independent manner by 
the two-electron-reducing enzyme DT-diaphorase (DTD; 
NAD(P)H:quinone oxidoreductase, NQO1) that can com-
promise hypoxic selectivity302–304. Nitroimidazole activation 
occurs via the step-wise addition of up to six electrons, with 
the reactions after the addition of the first electron being 
irreversible.
MMC and misonidazole showed early promise as biore-
ductive agents. However, the hypoxia-selectivity of both 
agents was deemed to be suboptimal (3–5-fold increased 
potency against hypoxic cells), with the clinical assessment 
of MMC in a “bioreductive context” being further hampered 
by its significant effects against well-oxygenated tumor cells. 
A methylated analog of MMC, porfiromycin, was developed 
that was a poorer substrate for DTD than the parental com-
pound and showed greater hypoxic selectivity305,306. Although 
preclinical studies were encouraging307, clinical trials 
showed little benefit over MMC when combined with radio-
therapy308. The indolequinone E09 was then developed. Like 
MMC, E09 is a substrate for both DTD and P450R309–311. As for 
porfiromycin, preclinical data supported the clinical devel-
opment of E09, but the clinical utility of the agent appeared 
compromised by very poor biodistribution and pharmacok-
inetics312. However, E09 has had a recent clinical revival in 
superficial bladder cancer where intravesical administration 
circumvents the delivery and clearance issues313,314.
Development of the nitroimidazoles progressed with 
the 2-nitroimidazole RSU1069: a modified misonidazole 
derivative that acts as a bi-functional alkylating agent by 
Figure 9. (Adapted from reference 125.) (A) Fluorescence analysis of HeLa cells treated with CAI during normoxia, hypoxia exposure, or upon reoxygen-
ation. (B) Quantitative fluorescence activated cell sorting (FACS) analysis of CAI binding to HeLa cells treated with CAI under the respective conditions. 
(C) Immunofluorescence analysis of HeLa cells treated with CAI during hypoxia or upon reoxygenation (green). The presence of CA IX was assessed 
using the monoclonal CA IX (M75) antibody (red). Co-localization of CAI sulfonamide and CA IX monoclonal antibody was assessed by merging the 
images (yellow). Significant differences are indicated by asterisks (*p < 0.001; **p < 0.01). Scale bars are 25 µm. (Reprinted with permission of Elsevier.)
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virtue of an aziridine ring315. The hypoxia-selectivity of 
RSU1069 was markedly improved compared with miso-
nidazole, and the agent showed excellent radioenhancing 
abilities in preclinical models316,317. As with many other 
bioreductive agents, one-electron reduction via P450R 
appears important in the bioactivation of RSU1069318,319. 
Despite the promising preclinical data, toxicity blocked 
the clinical development of this compound320. A prod-
rug variant of RSU1069 was produced (RB6145) to try 
and circumvent the toxicity issues321, but this gave rise to 
unexpected side effects in preclinical models322, blocking 
further development.
6.4.3. Clinical lead compounds
Despite the initial interest in quinone and nitroimidazole 
compounds, the most clinically advanced bioreductive 
agents are not from these agent classes. Tirapazamine 
is a heteroaromatic N-oxide that progressed to phase 
III development. Tirapazamine shows marked hypoxia 
selectivity in vitro and significantly enhanced both 
radiation and chemotherapy response in animal mod-
els (reviewed by Brown323). Further, tirapazamine in the 
neoadjuvant setting appears able to control metastatic 
dissemination from murine tumors324. Like MMC and the 
nitroimidazoles, one-electron reduction is important in 
the bioactivation of tirapazamine, with a role for P450R 
implied from preclinical studies318,325 Clinically beneficial 
schedules were reported in combination with standard 
chemotherapy (particularly platinum-based) and both 
radio- and chemoradiotherapy in phase II trials (sum-
marized in reference 326). However, not all of the results 
of phase III trials have concurred with the early phase 
successes, and the future development of tirapazamine is 
currently uncertain.
AQ4N (banoxantrone) belongs to the class of aliphatic 
N-oxides and is currently in phase I/II development. Upon 
reduction, AQ4N yields the cytotoxic product AQ4, via 
the AQ4M intermediate. Cytochrome p450s and induc-
ible nitric oxide synthase reportedly catalyze this conver-
sion, with little if any role implied for P450R327–329. Unlike 
tirapazamine where the cytotoxic species is a short-lived 
free radical, AQ4 is a stable cytotoxin that can potentially 
diffuse from the cell in which it is bioactivated and elicit 
a bystander effect in adjacent cells. Preclinical studies 
demonstrated clear benefits of AQ4N in combination with 
chemo-, radio-, and chemoradiotherapy330–334 (Williams 
et al., unpublished results), leading to clinical develop-
ment. Importantly, significant investment has been made 
into the identification of hypoxic biomarkers that co-
register with AQ4 accumulation335. This may facilitate the 
identification of patients likely to show the greatest benefit 
from combined treatment with AQ4N. The ability to stratify 
treatment response based on the extent of tumor hypoxia is 
of great importance in the assessment of the clinical benefit 
of bioreductive drugs, and has been used successfully with 
tirapazamine336 and trials using approaches to enhance 
oxygenation224 (ARCON).
6.4.4. New kids on the block
NLCQ-1 (NSC 709257) is the lead agent from a rational 
approach to develop nitroaromatics with weak DNA-
intercalating properties that may improve drug biodistribu-
tion (reviewed by Papadopoulou and Bloomer337). In vitro 
studies have established good hypoxia-selectivity ratios 
with NLCQ-1 and have highlighted the importance of one-
electron reductases in its bioactivation338 (Williams et al., 
unpublished observations). In vivo studies have shown 
that NLCQ-1 combines well with radiotherapy and a range 
of chemotherapy approaches and compares favorably with 
tirapazamine339–343. Importantly, beneficial combinations 
with chemotherapy are not at the expense of any increase 
in normal tissue toxicity337. As yet unpublished observations 
have also shown that NLCQ-1 is an excellent adjuvant to 
radiotherapy in the control of metastatic disease (Williams 
and Papadopoulou, manuscript in preparation).
PR-104 (Proacta) is the lead compound of a series of dini-
trobenzamide (DNBM) mustards that are activated under 
severe hypoxia344. A bystander effect is elicited as the cyto-
toxic metabolites are relatively stable. DNBMs were initially 
developed as analogs of the weak monofunctional alkylating 
agent CB1954. PR-104 is effectively a “pre-prodrug” in that 
it has been developed as a water-soluble phosphate ester 
that, once administered, releases the corresponding alcohol 
via the action of systemic phosphatases. Preclinical evalua-
tions described excellent hypoxic selectivity in vitro. Further, 
PR-104 exhibited single agent activity against a range of 
tumor xenografts, and enhanced both radio- and chemo-
therapeutic outcome345. PR-104 is currently in phase I trial 
in New Zealand and the USA in combination with docetaxel 
or gemcitabine in patients with solid tumors (NCT00459836, 
http://www.clinicaltrials.gov/).
RH1 is a novel aziridinylbenzoquinone alkylating agent 
that is also in phase I clinical trial in the USA (NCT00558727, 
http://www.clinicaltrials.gov/) and the UK346. Like E09, RH1 
is bioactivated by the oxygen-independent two-electron 
reductase DTD and the related NRH:quinone oxidoreduct-
ase 2 (NQO2)347. Substantial activity against DTD-expressing 
tumors has been demonstrated in vivo348. Importantly, 
side-by-side comparisons of E09 and RH1 suggest that the 
two drugs exhibit substantially different pharmacological 
properties that may favor a more general clinical utility of 
the latter compound348.
6.4.5. Conclusions
The potential of bioreductive agents to enhance the efficacy 
of standard therapies by targeting the most resistant tumor 
cells has long been recognized. Although numerous agents 
have proved excellent in preclinical models, translation to the 
clinic has been hampered by unforeseen side effects, phar-
macological barriers, and/or apparently poor efficacy. One 
significant contributing factor in clinical analysis is patient 
stratification. Although most solid tumors exhibit regions 
of hypoxia, the extent clearly differs, and this impacts on 
response. There is a real need to ensure that clinical studies 
in some way analyze tumor hypoxia to enable responses to 
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be correlated to the extent of the target population. Without 
this there is the possibility that extremely effective agents will 
fail, as their benefits in specific cohorts of patients will be 
masked by effectiveness against the population as a whole. 
There is certainly a shift toward biomarker analysis as a key 
input to early trial design, and this has particular relevance 
in the bioreductive arena for these agents to truly achieve 
their potential.
6.5. Synthesis of anti-carbonic anhydrase IX (CA IX) 
drugs
Unlike other CAs, which usually possess one polypeptide 
chain comprising just the catalytic domain293,349, CA IX is a 
multidomain, transmembrane protein possessing a more 
complex organization (Figure 10), and consists of: (1) a 
small intracytosolic (IC) tail whose function is unknown; (2) 
a short transmembrane segment (TM); (3) the extracellular 
catalytic (CA) domain, which shows high sequence homolgy 
with that of other -CAs350; (4) a proteoglycan-like (PG) 
domain unique to this CA isozyme, which is critical to cell 
adhesion processes in which this protein is involved293,350; 
and (5) a short signal peptide (SP). Many experiments have 
been performed with the PG-deleted (PG) or catalytic 
domain-deleted (CA) constructs of this protein in order to 
understand the role(s) of the various domains in its function 
and role in tumorigenesis125,350. The X-ray crystal structure of 
CA IX is unknown, but recent experiments led to the conclu-
sion that it forms dimers linked by disulfide bonds351.
Many CAs present in the human body possess very high 
catalytic activity for the physiological reaction, i.e. hydration 
of carbon dioxide to bicarbonate and a proton, and CA IX 
is among such high-activity isoforms293,350, as seen from the 
data of Table 2. As with all other -CAs investigated up to 
now293, the catalytic domain of CA IX contains a critically 
important Zn(II) ion coordinated by three histidine residues 
(i.e. His94, His96, and His119; CA I numbering293) and a water 
molecule, which by deprotonation assisted by the active site 
residue His64 (CA I numbering for historical reasons293) 
leads to the zinc-hydroxide form that acts as the nucleophilic 
species in the catalytic cycle293. CA IX together with CA II 
are highly active catalysts for the CO
2
 hydration reaction, 
being among the most effective enzymes known in nature, 
as shown in Table 2351. CA IX is also susceptible to inhibi-
tion by anions and sulfonamides/sulfamates/sulfamides, 
as with all the other -CAs293, the inhibitors coordinating 
directly with the metal ion within the active site cavity and 
participating in various other favorable interactions with 
amino acid residues situated in both the hydrophobic and 
hydrophilic halves of the active site293. Many low-nanomolar 
CA IX inhibitors have been detected in the last several years 
(Figure 11)131,293,352,353.
The involvement of CAs and of their sulfonamide inhibi-
tors in cancer has been investigated recently, as mentioned 
above125,293,295. Many potent CA inhibitors derived from aceta-
zolamide, ethoxzolamide, and other aromatic/heterocyclic 
sulfonamide scaffolds were shown to inhibit the growth of 
several tumor cell lines in vitro and in vivo293.
Some of the most interesting CA IX inhibitors available at 
this time among the many such derivatives reported293 are 
the compounds investigated by Svastova et al.125 (possessing 
structures 1 and 2) for their in vivo role in tumor acidifica-
tion. These compounds present a special interest, because 
derivative 1 is a fluorescent sulfonamide with high affin-
ity for CA IX (inhibition constant (K
i
) of  24 nM)293, which 
was shown to be useful as a fluorescent probe for hypoxic 
tumors293,354. This inhibitor binds only to CA IX under 
hypoxia in vivo125,295. Although the biochemical rationale 
for this phenomenon is not understood at this point, these 
properties may be exploited for designing diagnostic tools 
for the imaging of hypoxic tumors125,295. Compound 2 on 
the other hand, which is also a very strong CA IX inhibitor 
(K
i
 of  14 nM)125,295, belongs to a class of positively charged, 
membrane-impermeant compounds previously reported 
by one of our groups355, which are highly attractive for tar-
geting CA IX with its extracellular active site, since such 
compounds do not inhibit intracellular CAs, and may thus 
lead to drugs with fewer side effects as compared to the 
currently available compounds (acetazolamide is the pro-
totypical one293), which indiscriminately inhibit all CAs293. 
The X-ray crystal structure of compound 2 in adduct with 
CA II (whose active site is very similar to that of CA IX, as 
shown recently by homology modeling) has been reported 
recently356. It has been observed that the positively charged 
Figure 10. Domain organization of the CA IX protein350. SP, signal 
 peptide; PG, proteoglycan-like domain (residues 42–130); CA, catalytic, 
carbonic anhydrase domain (residues 167–405); TM, transmembrane 
segment; IC, intracellular tail.
Table 2. Kinetic parameters for CO
2
 hydration reaction catalyzed by the 
13 vertebrate catalytically active -CA isozymes, at 20°C and pH 7.5, and 
their subcellular localization293.
Isozyme k
cat
 (s−1) K
m
 (mM)
k
cat
/K
m
 
(M− 1 s−1) Subcellular localization
hCA I 2.0 × 105 4.0 5.0 × 107 Cytosol
hCA II 1.4 × 106 9.3 1.5 × 108 Cytosol
hCA III 1.3 × 104 52.0 2.5 × 105 Cytosol
hCA IV 1.1 × 106 21.5 5.1 × 107 Membrane-bound
hCA VA 2.9 × 105 10.0 2.9 × 107 Mitochondria
hCA VB 9.5 × 105 9.7 9.8 × 107 Mitochondria
hCA VI 3.4 × 105 6.9 4.9 × 107 Secreted into saliva/milk
hCA VII 9.5 × 105 11.4 8.3 × 107 Cytosol
hCA IX 1.1 × 106 7.5 1.5 × 108 Transmembrane
hCA XII 4.2 × 105 12.0 3.5 × 107 Transmembrane
hCA XIII 1.5 × 105 13.8 1.1 × 107 Cytosol
hCA XIV 3.1 × 105 7.9 3.9 × 107 Transmembrane
mCA XV 4.7 × 105 14.2 3.3 × 107 Membrane-bound
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pyridinium derivative 2 favorably binds within the enzyme 
active site, coordinating with the deprotonated sulfonamide 
moiety to the catalytically critical Zn(II) ion. It also partici-
pates in many other favorable interactions with amino acid 
residues present in the active site cavity, among which is a 
stacking between the trimethylpyridinium ring of inhibitor 
2 and the phenyl ring of Phe131, an amino acid important 
for the binding of inhibitors to CAs356. A similar binding 
was subsequently reported for the fluorescein derivative 
1357. Thus, such structures can be used for the rational drug 
design of more isozyme IX-selective and potent CA inhibi-
tors293. It should be mentioned that since the X-ray structure 
of CA IX is not yet available, most studies used the CA II 
structure for modeling and designing CA IX inhibitors. We 
stress again that positively charged compounds, of which 
2 is a representative, may have the advantage of selectively 
SO2NH2 SO2NH2
SO2NH2
HN
NN
HN
NN
N
Ki(hCAIX)= 0.15nM
Ki(hCAII)/Ki(hCAIX)=706
Ki(hCAIX)= 0.12nM
Ki(hCAII)/Ki(hCAIX)=166
Ki(hCAIX)= 0.34nM
Ki(hCAII)/Ki(hCAIX)=247
N N OEtCl Eto
HN
NN
N OEtEto
Figure 11. Structures of anti-carbonic anhydrase IX (CA IX) derivatives.
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inhibiting only CA IX in vivo, due to their membrane 
impermeability356.
Indisulam 3 is a sulfonamide derivative (originally called 
E7070) discovered through extensive screening/synthetic 
studies, which showed powerful anticancer activity in vitro 
and in vivo349. Indisulam has been also shown to act as a 
CA IX nanomolar inhibitor358. However, its mechanism of 
action is not clearly elucidated, as the drug was shown to be 
involved in the perturbation of the cell cycle in the G
1
 and/
or G
2
 phases, the down-regulation of cyclins, the reduction 
of CDK2 activity, the inhibition of pRb phosphorylation, and 
differential expression of molecules known to participate in 
cell adhesion, signaling, and immune response, in addition 
to its CA IX inhibitory properties. Indisulam showed in vivo 
efficacy against human tumor xenografts in nude mice and 
exhibited significant anti-tumor effect, and has progressed 
to phase I and phase II clinical trials for the treatment of 
solid tumors293.
Among the many compounds developed ultimately for 
targeting CA IX, one must also mention the 1,3,5-trazine 
derivatives incorporating benzenesulfonamide tails, of types 
4–6, which showed excellent selectivities for inhibition of the 
tumor-associated isoform IX over the cytosolic, ubiquitous 
form CA II, with selectivity ratios in the range of 166–706359.
The bioreductive, disulfide-type derivative 8, which is 
converted to the thiol 7 by reduction under hypoxic condi-
tions, is also of great interest due to its excellent selectivity 
ratio for inhibition of the tumor-associated enzyme (CA IX) 
over the cytosolic ones, and for its properties of prodrug360.
In conclusion, with its overexpression in many cancer tis-
sues and not in their normal counterparts, CA IX constitutes 
an interesting target for novel approaches in the design of 
anticancer therapies. CA IX is crucial for tumor pH regula-
tion, contributing both to the acquisition of metastasic 
phenotypes and to chemoresistance with some anticancer 
drugs. Consequently, further research needs to be done in 
the field of the tumor-associated CA IX in order to better 
understand its exact role in cancer. CA IX-selective inhibitors 
are now available, and they constitute interesting tools for 
studying the physiological and/or pathological effects of this 
enzyme. Indisulam, a sulfonamide anti-cancer drug, is actu-
ally in clinical trials, phase II. In addition to its hypothetical 
action in perturbing the cell cycle, it provides a potent inhi-
bition of CA. However, given that multiple pathways contrib-
ute to tumor growth, anti-tumor activity may be increased 
by agents targeting multiple pathways, including CA IX, or 
by the combination of several agents to allow inhibition of 
multiple pathways. Recently, the design of CA IX-selective 
inhibitors containing a variety of scaffolds and with interest-
ing physiocochemical properties has also been achieved. 
New sulfonamides, sulfamates, and sulfamides have been 
synthesized, with some of these derivatives strongly inhibit-
ing CA IX, with inhibition constants in the low-nanomolar 
range, and also with excellent selectivity ratios for inhibition 
of the tumor-associated over the cytosolic CAs. Thus, many 
biochemical, physiological, and pharmacological novel data 
point to the possible use of inhibition of the tumor-associated 
isozyme CA IX in the management of hypoxic tumors which 
do not respond to the classical chemo- and radiotherapy. 
There are possibilities of developing both diagnostic tools 
for the non-invasive imaging of these tumors, as well as 
therapeutic agents that probably perturb the extratumoral 
acidification in which CA IX is involved. Much pharma-
cologic work is however warranted in order to understand 
whether a successful new class of anti-tumor drugs may be 
developed, starting from these preliminary but encouraging 
observations.
6.6. Targeting CA IX in tumors
CA IX possesses several properties determined by its distri-
bution, localization, and function, which make it a suitable 
molecular target for cancer therapy291. First, it is almost 
exclusively associated with solid tumors, predominantly 
those resistant to conventional chemotherapy and radio-
therapy, as demonstrated by numerous studies of different 
tumor types. Second, it is exposed on the surface of cancer 
cells and is thus accessible to antibodies or inhibitors. Third, 
CA IX is a highly active enzyme that plays a role in hypoxic 
tumor phenotype and can therefore serve as a functional 
therapy target. This has been experimentally demonstrated 
using RNA interference or deletion of the catalytic domain, 
respectively, which resulted in decreased survival of CA 
IX-expressing tumor cells and reduced growth of tumor 
xenografts361 (Barathova et al., manuscript in preparation).
Tight association of CA IX with tumor phenotype rep-
resents a considerable advantage for immunotherapeutic 
targeting of CA IX-positive tumor cells. This approach has 
been extensively and thoroughly studied in preclinical renal 
cell carcinoma (RCC) models, as well as in RCC patients, 
using the CA IX-specific monoclonal antibody G250 and its 
 chimeric and bispecific variants362,363. Chimeric G250 (con-
taining variable regions of the mouse G250 and constant 
regions of the human immunoglobulin G (IgG)), known 
under the commercial name Rencarex®, is currently in a 
phase III clinical trial as an adjuvant therapy of patients with 
non-metastatic RCC with high risk of recurrence.
Monoclonal antibodies are not the only immunothera-
peutic tools developed against CA IX-expressing tumors. 
Other approaches include different types of vaccines (anti-
idiotype, dendritic cell-based, oligopeptide, and  chimeric 
protein vaccines) and genetically engineered cytotoxic 
cells (reviewed in reference 291). These approaches showed 
promising results when tested in preclinical settings.
Rationale for the use of CA inhibitors as anti-cancer 
drugs is based on the assumption that perturbation of 
pH control in tumor tissue via diminished bicarbonate 
production/import could lead to decreased survival of 
tumor cells or their increased capacity to accumulate 
therapeutic drug293. Various CA inhibitors were studied 
using two-dimensional (2D) and 3D in vitro models and 
showed a capacity to block pH regulation in hypoxia125,127. 
Although these promising drugs now attract considerable 
attention, their potential anti-cancer effects need further 
investigation.
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6.7. ROS and redox measurements and research potential 
in oncology
The adequate supply of oxygen is mandatory for the function 
of diverse processes within all aerobic organisms. Thereby 
O
2
 can often be transformed into highly reactive derivates, 
called reactive oxygen species (ROS). In the eukaryotic cell, 
ROS can be generated through multiple sources including 
the electron transport chain in mitochondria, ionizing radi-
ations, and through enzymes producing superoxide anion 
radicals. Superoxide anion radical formation is often the 
initial step in ROS generation. Given that superoxide anion 
radicals and ROS are cytotoxic, cells have developed antioxi-
dant mechanisms which include enzymes that dismutate 
O2– into H
2
O
2
 (superoxide dismutases), or degrade H
2
O
2
 
(catalase, glutathione peroxidases, and peroxiredoxins). 
When cellular production of ROS overwhelms its antioxi-
dant capacity, a state of oxidative stress is reached, leading 
to serious cellular injuries contributing to the pathogenesis 
of several diseases. Compelling evidence exists that high 
levels of ROS can damage DNA, RNA, lipids, and proteins, 
thus helping to initiate tumors. Interestingly, ROS produc-
tion is a mechanism shared by many non-surgical thera-
peutic approaches for cancers, including chemotherapy, 
radiotherapy, and photodynamic therapy, due to their 
implication in triggering cell death; therefore, ROS are also 
used to kill cancer cells. On the other hand, if generated in 
lower concentrations, ROS can act as second messengers in 
signal transduction and gene regulation. Indeed, ROS have 
been shown to act as important messengers in promoting 
the growth of tumor cells by activating important signaling 
pathways. ROS have also been shown to increase the growth 
of new vessels, angiogenesis, a process highly important to 
tumor growth. Finally, ROS can increase the activity of HIF, 
a major signaling element in the response to hypoxia. Since 
the formation of ROS requires molecular oxygen, it has 
been suggested that ROS may be involved in the response to 
hypoxia. Indeed, there has been a long-lasting debate about 
the role of ROS under hypoxic conditions stimulated by the 
ideas that: (1) a heme protein functioning as an oxidase gen-
erates ROS as signaling molecules; (2) ROS derived from the 
mitochondrial respiratory chain could contribute to oxygen 
signaling; or (3) ROS production may be linked to the activity 
of signaling components upstream of HIF, such as hydroxy-
lases or kinases. A variety of sources contribute to cellular 
ROS generation, including the mitochondrial respiratory 
chain and NADPH oxidases, and both sources have been 
associated with tumor growth364,365.
Recent evidence suggests that in addition to chronic 
hypoxia, also periods of cycling or intermittent hypoxia 
occur in tumors, mostly due to the not fully functional 
tumor vasculature, which lead to heterogeneous oxygena-
tion within the tumor. Moreover, reoxygenation events 
after hypoxia/ischemia have been associated with elevated 
ROS production in many disorders, suggesting that peri-
ods and regions of elevated ROS may also occur within a 
tumor. Both chronic as well as intermittent hypoxia have 
been associated with tumor progression and resistance 
to therapy366,367. In fact, intermittent hypoxia has been 
 suggested to more effectively up-regulate the HIF system 
than chronic hypoxia368,369 and to be of major importance 
for tumor progression370.
However, the importance of ROS either as therapeutic, 
cytotoxic molecule or as signaling molecule under the differ-
ent oxygen conditions in a tumor and its specific relevance 
for the outcome to therapy are not clear. In fact, it has been 
convincingly demonstrated that ROS levels either increase 
or decrease under hypoxic conditions364,365,371–373.
These contradictory effects have been associated with 
 differences in the methodological approaches, in the cell 
types investigated, in the metabolic state of the cells, in the 
disease context, and so on. However, no clear explanation 
has been provided for the divergent findings to date. Again, 
given the potential importance of ROS production for tumor 
growth and therapeutic sensitivity, it will be of major rel-
evance to be able to assess ROS levels within the heteroge-
neous tumor microenvironment, to identify the sources and 
conditions of ROS production, and to investigate the specific 
role of ROS and the redox state for any therapeutic outcome. 
One may speculate that selectivity between tumor and 
non-tumor cells may depend on differences of their redox 
environments, since tumor cells have been associated with 
elevated levels of ROS374.
A set of different cellular parameters including ROS levels, 
oxygenation, metabolic redox status, antioxidant enzyme 
expression, cell signaling, and transcription factor activation 
profiles, namely a “redox signaling signature,” is awaiting 
development. This could help to design ROS-elevating or 
ROS-depleting therapies specific to certain types of cancer 
cells in consideration of the detailed microenvironmental 
conditions. In a clinical setting, individualized choice of an 
optimal ROS-manipulation therapy would require in addi-
tion accurate and convenient measurements for ROS as well 
as the “redox signaling signature” for prediction of  efficacy 
and systemic toxicity.
To date there are several methods in use, mainly detect-
ing ROS in cultivated cells. Extracellular ROS levels can be 
detected using cytochrome c reduction or chemilumines-
cence. Intracellular ROS levels are mainly determined by 
fluorescent dyes, including dichlorofluorescein (DCF), 
dihydroethidine (DHE), or dihydrorhodamine (DHR), or 
by use of a redox-sensitive FRET probe. However, none of 
these latter methods is specific for a certain type of ROS. 
In addition, ROS can also be determined in frozen tis-
sues by staining with the fluorescent dyes such as DCF or 
DHE364,372,373. However, to date, the most specific approach 
to detect superoxide anion radicals and other free radicals 
intra- or extracellularly is based on electron spin resonance 
(ESR). During the course of EUROXY, we developed an ESR 
method to specifically assess the ROS levels at any given 
oxygen concentration within the measurement tube by 
attaching a special gas mixture unit to the ESR device. This 
approach is rather specific for superoxide radicals depend-
ent on the spin traps and compounds used. It can be used 
for cultivated cells, blood, and tissues.
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However, although an important step forward, there is 
still no good approach to determine ROS levels in situ in 
a tumor or other tissue within the whole organ or organ-
ism. Important developments have been made regarding 
3D in vivo imaging of oxygen distribution using electron 
paramagnetic resonance (EPR) within tumors and different 
organs. However, there is still no sufficient approach to reli-
ably measure ROS in situ in a living organ with an adequate 
resolution375. This would be helpful in assessing the role of 
ROS in different microenvironments, under defined oxygen 
concentrations, within a tumor, in controlling tumor growth 
and therapeutic sensitivity, and a step forward toward an 
individualized optimal ROS-manipulation therapy.
7. Concluding remarks
The combined effort of the participating academic research 
groups and small companies has enabled us to indicate a 
few promising targets for tumor imaging and therapy among 
the major pathways active in tumor cell adaptation to hyp-
oxia and to develop supporting equipment.
Moderate hypoxia seems to be where HIF is most active, 
while at deeper hypoxia (1300 ppm O
2
) cell arrest in S-phase 
is a central event, and at deep hypoxia (under 1000 ppm O
2
) 
the inhibition of ribonucleotide reductase activity and thus 
DNA synthesis arrest is a key event.
The working of the transcription factor HIF that is acti-
vated by both genetic and microenvironmental factors is 
reasonably well known. A particularly interesting fact is that 
the oxygen-sensing PHD enzymes themselves are under 
regulatory control. The same degree of detailed knowledge 
is not yet at hand for the two other major oxygen-sensitive 
pathways, UPR and mTOR, both of which, through transla-
tional control, may be as important for shaping cell pheno-
type in response to hypoxia. Cross-talk takes place between 
pathways, and other factors such as pH and redox processes 
also participate. Furthermore, many oncogenic signaling 
pathways overlap with hypoxia-induced pathways. The con-
sortium’s gene expression profiling of hypoxic tumor tissues 
demonstrated the prognostic value of these patterns.
Much effort has successfully focused on improving imag-
ing using positively charged sulfonamide CA IX inhibitor, 
binding to the extracellular CA IX domain of the CA IX. This 
splicing variant of CA IX is nearly exclusively expressed in 
the hypoxic and acidic tumor environment. This domain, 
therefore, appears to be a promising target for imaging 
the hypoxic areas of solid tumors. Our in vivo experiments 
 support this notion.
CA IX inhibitors may also be found useful as cancer 
 therapeutic agents in combination with proton pump 
inhibitors, working by decreasing intracellular pH. Another 
promising agent is the bioreductive compound NLCQ-1, 
which inhibits metastasis in animal tests.
Simultaneously with the work on molecular and cellular 
biology, participating small companies have developed 
new equipment: oxygen-sensing flasks, combined mini 
clean room and incubator, combined incubator and flow-
through culture system, a redox sensor based on spec-
troscopy, and a new redox sensor based on electron spin 
resonance.
A general translation of our results into clinical studies 
will take place in the new EU-funded project Metoxia, run-
ning from 2009 to 2012. In this project, most of the EUROXY 
partners will continue and be complemented by a number 
of cancer clinics that have ongoing imaging and drug testing 
programs.
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